User guide for micro, small and medium-sized enterprises

on the administrative and procedural aspects of the provisions laid down in regulation (EC) No 726/2004, that are of particular relevance to SMEs
User guide for micro, small and medium-sized enterprises

on the administrative and procedural aspects of the provisions laid down in Regulation (EC) No 726/2004, that are of particular relevance to SMEs

SME Office

Addressing the needs of small and medium-sized enterprises

Latest revised version – July 2016
# Table of contents

1. INTRODUCTION ................................................................................................................ 8
   1.1. Obtaining a marketing authorisation within the European Union .............................. 8
      1.1.1. European Union marketing authorisation – the centralised procedure...... 9
      1.1.2. National marketing authorisations – national, mutual recognition & decentralised procedures ................................................. 9
      1.1.3. Overview of (data) requirements for obtaining marketing authorisation in the EU ................................................................. 10
   1.2. EU legislative framework for pharmaceuticals ......................................................... 10
      1.2.1. Implementation of adopted legislation ......................................................... 12
      1.2.2. Upcoming legislative changes .................................................................. 12

2. SME INITIATIVE ........................................................................................................... 15
   2.1. Objective .................................................................................................................. 16
   2.2. Definition of an SME ........................................................................................... 16
   2.3. Role of the SME office ......................................................................................... 16
   2.4. Incentives for SMEs (EU provisions and national provisions) ............................... 16
      2.4.1. Incentives offered by EMA ........................................................................ 16
      2.4.2. Other EU incentives for SMEs ................................................................. 19
      2.4.3. National provisions for SMEs .................................................................. 19
   2.5. How to request SME status .................................................................................. 19
      2.5.1. Assignment of SME status ....................................................................... 19
      2.5.2. Newly established or non-EEA enterprises .............................................. 20
      2.5.3. Maintenance of SME status .................................................................... 20

3. SUPPORT TO MEDICINAL PRODUCT DEVELOPMENT ........................................ 23
   3.1. Innovation task force (ITF) .................................................................................. 24
   3.2. PRIority MEdicines (PRIME) scheme (human medicines only) ......................... 24
   3.3. Advanced therapy medicinal products (ATMPs) .................................................... 24
      3.3.1. Classification procedure as an ATMP ...................................................... 24
      3.3.2. Certification for ATMPs ........................................................................ 25
   3.4. Scientific advice/protocol assistance .................................................................... 25
      3.4.1. Scope of scientific advice ....................................................................... 25
      3.4.2. Fee reductions for scientific advice ....................................................... 26
   3.5. Scientific guidelines and position papers ............................................................. 27
4. MEDICINAL PRODUCT DEVELOPMENT (HUMAN) ..................................29

4.1. Quality ................................................................................................................30
  4.1.1. Active substance (drug substance) ...........................................................30
  4.1.2. Finished product (drug product) ...............................................................33
  4.1.3. Other specific issues .................................................................................34

4.2. Non-clinical development ...................................................................................34
  4.2.1. Pharmacology ...........................................................................................35
  4.2.2. Pharmacokinetics & Metabolism ...............................................................35
  4.2.3. Toxicology & Toxicokinetics .....................................................................35

4.3. Clinical development ...........................................................................................37
  4.3.1. Human pharmacology studies (phase I) ...................................................37
  4.3.2. Therapeutic exploratory studies (phase II) ...............................................37
  4.3.3. Clinical efficacy and safety (phase III) .......................................................37
  4.3.4. Therapeutic use/clinical utility (traditionally phase IV) ...........................38
  4.3.5. Adaptive designs ......................................................................................38
  4.3.6. Clinical trials – notice to applicants .........................................................38

4.4. Measures for orphan medicines .......................................................................40

4.5. Paediatric development ......................................................................................41

4.6. GMP/GDP/GCP/GLP ..........................................................................................43
  4.6.1. Good manufacturing practice (GMP) .........................................................43
  4.6.2. Good distribution practice (GDP) ..............................................................44
  4.6.3. Good clinical practice (GCP) .....................................................................44
  4.6.4. Good laboratory practice (GLP) .................................................................44
  4.6.5. Inspections ...............................................................................................45

5. MEDICINAL PRODUCT DEVELOPMENT (VETERINARY) .........................47

5.1. Maximum residue limits (MRL) .......................................................................48

5.2. Quality ...............................................................................................................49

5.3. Safety ................................................................................................................49

5.4. Efficacy ..............................................................................................................49

5.5. Immunologicals ...............................................................................................50

5.6. GMP/GDP/GLP/GCP ..........................................................................................50

5.7. MUMS/limited market products .....................................................................50
6. APPLICATION FOR CENTRALISED MARKETING AUTHORISATION ......53

6.1. Access to the centralised procedure
6.2. Selection of rapporteur/co-rapporteur
6.3. (Invented) Name of products evaluated via the centralised procedure
6.4. EMA contact point in the centralised procedure
6.5. EMA pre-submission meeting
6.6. Compilation of the application dossier
6.7. Submission and validation of the application dossier
6.8. Evaluation of the application
6.9. Re-examination of the CHMP/CVMP opinion
6.10. Conditions to the marketing authorisation
6.11. Post-authorisation efficacy studies (PAES)
6.12. Publication of clinical data for medicinal products for human use (‘policy 0070’)
6.13. Decision-making process
6.14. Early access to the EU market
6.14.2. Conditional marketing authorisation (human medicines only)
6.14.3. Compassionate use
6.14.4. Marketing authorisation under exceptional circumstances
6.14.5. Adaptive pathways
6.15. Marketing of a centrally authorised product in the Union

7. RISK MANAGEMENT AND PHARMACOVIGILANCE ....................67

7.1. Good pharmacovigilance practices (GVP)
7.2. Key aspects of the current EU pharmacovigilance system
7.3. Reporting obligations
7.3.1. Sponsors of clinical trials – reporting obligations
7.3.2. MAHs of medicinal products authorised in EEA - reporting obligations
7.4. EudraVigilance
7.5. EVWEB
7.6. Pharmacovigilance for veterinary medicinal products

8. OTHER USEFUL INFORMATION ............................................77

8.1. Information on medicinal products
8.2. Contact points at EMA

ANNEXE 1 ............................................................................81

National provisions for SMEs applicable to the pharmaceutical sector
Appendix
1. INTRODUCTION
1. Introduction

This guide has been prepared for micro, small and medium-sized enterprises (‘SMEs’) operating in the pharmaceutical sector. Its aim is to facilitate understanding of the main aspects of medicinal product legislation. The guide is structured to follow the chronological stages of developing a medicinal product. An overview of the scientific data requirements for obtaining a marketing authorisation in the European Union (‘EU’) is provided. The regulatory procedures in place to optimise development and obtain an EU marketing authorisation are also summarised.

The guide focuses primarily on the requirements for authorising medicinal products for human or veterinary use. The guide is not intended to be an exhaustive document but rather to raise SMEs’ awareness of the various more detailed sources of information available.

In December 2005, Commission Regulation (EC) No 2049/20051 (‘SME Regulation’) introduced provisions aimed at promoting innovation and the development of new medicinal products for human and veterinary use by SMEs. This guide is intended to fulfil the obligation laid down in Article 12 of the SME Regulation, which calls on the European Medicines Agency (‘EMA’ or ‘Agency’) to publish a ‘User Guide’ on the administrative and procedural aspects of medicines legislation which are of particular relevance to SMEs.

Pursuant to the SME Regulation, companies can access financial assistance (in the form of fee reductions and deferrals) and administrative assistance from the Agency, details of which are outlined in section 2 of this guide. To facilitate contact with the Agency, a ‘SME Office’ was launched in December 2005 and is dedicated to addressing the particular needs of smaller companies.

Any feedback on the content or format of this guide should be forwarded to the SME office: sme@ema.europa.eu.

1.1. Obtaining a marketing authorisation within the European Union

Prior to marketing a medicinal product2 in the EU, a marketing authorisation (product licence) must be obtained. The company who holds the authorisation to place the medicinal product on the market and who is legally responsible for marketing the medicinal product (so-called ‘marketing authorisation holder’), must be “established”3 within the EEA (Iceland, Liechtenstein, Norway and the Member States of the European Union).

In the EU, there are two types of marketing authorisation:

- **National marketing authorisations:** issued by the competent authorities of individual Member States. The medicinal product may be put on the market in all Member States that have granted an authorisation for it.

- **European Union marketing authorisation:** granted by the European Commission, following a positive opinion from the Agency. This is a single authorisation that allows the medicinal product to be put on the market in all Member States.

Approved conditions of use are laid down in the summary of product characteristics4 (prescribing information for health professionals), the labelling and the package leaflet for users5.

This user guide will focus on the use of the centralised procedure for obtaining an EU marketing authorisation. Further information on the regulatory routes for obtaining national marketing authorisations, namely the mutual

---

3) Being established shall be understood as having a permanent legal structure (formed in accordance with the law of an EU Member State or other EEA country). That allows the concerned person to assume the duties and responsibilities as well as to perform the tasks laid down by Union law. For reference on establishing see point 2 of Chapter I, Vol. 2A (human medicines) or 6A (veterinary medicines) of the Notice to Applicants: http://ec.europa.eu/health/documents/eudralex/index_en.htm
1.1.1. European Union marketing authorisation – the centralised procedure

The European Medicines Agency coordinates the existing scientific resources of the Member States to evaluate and supervise medicinal products for both human and veterinary use throughout the European Union. EMA is primarily involved in the centralised procedure for obtaining an EU marketing authorisation.

The Agency also gives scientific advice to research-based companies on the development of new medicinal products (see section 3.4) and develops guidelines on quality, safety and efficacy testing requirements (see section 3.5).

For queries relating to: orphan designation, paediatric investigation plans, scientific advice, filing an application for marketing authorisation through the centralised procedure, and EudraVigilance, the Agency is the primary point of contact.

If a SME has any doubt about the appropriate point of contact for a particular issue, the SME office can provide assistance: sme@ema.europa.eu

The centralised procedure is mandatory for certain types of medicinal products and optional for others. Medicinal products (both for human and veterinary use) developed by means of one of specified biotechnological processes⁷, veterinary medicinal products intended primarily for use as performance enhancers, advanced therapy medicinal products (ATMPs) for human use, human medicinal products containing a new active substance for treatment of acquired immune deficiency syndrome, cancer, neurodegenerative disorders, diabetes, viral diseases, auto-immune diseases/other immune dysfunctions and designated orphan medicinal products fall within the mandatory scope and must be filed centrally at EMA.

The centralised procedure is optional for products containing new active substances for indications other than those stated above and for products which constitute a significant therapeutic, scientific or technical innovation, or products for which the granting of the Union authorisation would be in the interest of patients or animal health at EU level. It is also optional for immunological veterinary medicinal products for the treatment of animal diseases that are subject to EU prophylactic measures. Companies, which intend to apply for the EU authorisation, should confirm eligibility for evaluation through the centralised procedure with EMA at least 7 months prior to submitting the centralised marketing application (see section 6.1).

In order to obtain the EU authorisation, an application must be submitted to EMA. The scientific evaluation of the application is carried out by the Committee for Medicinal Products for Human Use (CHMP) or the Committee for Medicinal Products for Veterinary Use (CVMP) of EMA, and a scientific opinion is prepared also in co-operation with the other EMA committees, as applicable. The opinion is sent to the European Commission, which drafts a decision and, having consulted the Member States through the relevant Standing Committee, adopts the decision and grants a marketing authorisation.

Such a marketing authorisation is valid throughout the Union and confers the same rights and obligations in each of the Member States as a marketing authorisation granted by that Member State.

The centralised procedure is briefly described in section 6 of this guide. Chapters 4 and 6 of Volume 2A and Volume 6A of the Notice to Applicants⁸ should be consulted for further information.

1.1.2. National marketing authorisations – national, mutual recognition & decentralised procedures

Each Member State of the European Union, plus Iceland, Liechtenstein and Norway, has its own national authority responsible for regulating medicinal products for human and veterinary use. These authorities have a common website⁹ called the Heads of Medicines Agencies website that serves as a useful connection point to the websites of individual authorities.

⁷) Recombinant DNA technology, controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells or hybridoma and monoclonal antibody methods (see Annex of Regulation no 726/2004).
⁹) http://www.hma.eu/
The authorities of the Member States are responsible for granting marketing authorisations for medicinal products placed on their markets, with the exception of medicinal products subject to centralised procedure. If a company seeks a national marketing authorisation, an application must be submitted to the competent authority of the Member State concerned. If a company is seeking a national marketing authorisation in more than one Member State, the mutual recognition or decentralised procedure are available to facilitate the granting of harmonised national authorisations across the Member States. Chapter 2 of Volume 2A and Volume 6A of the Notice to Applicants\(^{10}\) should be consulted for further information.

### 1.3. Overview of (data) requirements for obtaining marketing authorisation in the EU

An application for marketing authorisation for a new medicinal product for human use must generally be accompanied by the particulars and documents set out in Article 8(3) and Annex I of Directive 2001/83/EC\(^{11}\). The requirements include data generated from pharmaceutical (physicochemical, biological or microbiological) tests, non-clinical (toxicological and pharmacological) tests and clinical trials, evaluation of the potential environmental risks posed by the medicinal product, as well as a risk management plan and a summary of the pharmacovigilance site master file (see sections 4.1-4.3 and 7.0). For new medicines there is a requirement to agree a paediatric investigation plan and/or deferral and/or waiver with EMA early in development (see section 4.5).

Article 12(3) and Annex I to Directive 2001/82/EC\(^{12}\) list the requirements for the individual sections of the dossier that need to be submitted as part of the application for authorisation of a veterinary medicinal product.

An overview of the key issues to be addressed in the development of medicinal products for human use and veterinary use are outlined in section 4 and 5 of this guide respectively.

### 1.2. EU legislative framework for pharmaceuticals

All EU legislative texts are published in the Official Journal of the European Union (OJEU) in all official EU languages\(^{13}\).

The directives and regulations listed in the table on page 11 are available in the EudraLex section\(^{14}\) of the European Commission’s health website. These legislative texts — together with Directive 2001/20/EC\(^{15}\) and Commission Directive 2005/28/EC\(^{16}\) relating to good clinical practice concerning the conduct of clinical trials on medicinal products for human use and Directives 2003/94/EC and 91/412/EEC on good manufacturing practice (for human medicinal products and veterinary medicinal products respectively) — form the legislative backbone of medicinal product regulation in the EU. The Notice to Applicants facilitates the interpretation and application of the EU pharmaceutical legislation and should be consulted by any potential applicant for the EU marketing authorisation. It is not legally binding, and companies should always refer to the legal texts themselves for legislative requirements.


EU LEGISLATIVE FRAMEWORK FOR PHARMACEUTICALS

Commission Regulation 2049/2005\(^{17}\) of 15 December 2005 introduces provisions for SMEs.


Regulation (EC) No 847/2000\(^{23}\) of 27 April 2000 lays down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts 'similar medicinal product' and 'clinical superiority'.


---

1. INTRODUCTION

1.2.1. Implementation of adopted legislation

Regulation (EC) No 536/2014\(^{29}\) (‘Clinical Trials Regulation’\(^{30}\)) simplifies the rules for conducting clinical trials in the EU, aiming to speed up and simplify authorisation and reporting procedures, while maintaining the highest standards of patient safety and robustness of data. It also aims to better differentiate the obligations according to the risk-profile of the trial and improve clinical trials transparency including those conducted in third countries. The regulation will replace the ‘Clinical Trials Directive’ of 2001 (Directive 2001/20/EC) which sets out the current requirements for conducting clinical trials in the EU.

The new legislative framework entered into force on 16 June 2014 but will become applicable as soon as the EU Portal and the EU database will be declared fully operational\(^{31}\). The Clinical Trial Regulation indeed requires EMA to develop and maintain such a clinical trial portal and database to be used for the submission, authorisation and supervision of trials in the EU. It will serve as the source of public information on the clinical trial applications assessed, and all clinical trials conducted in the EU.

1.2.2. Upcoming legislative changes

Revision of the legal framework for veterinary medicinal products

The European Commission is currently undertaking a review of the legislation on veterinary medicinal products. The purpose of this revision is to increase the availability of veterinary medicinal products, to reduce the administrative burden on enterprises, to improve the functioning of the internal market for veterinary medicinal products and to assess the possibilities to have an improved response to antimicrobial resistance related to the use of veterinary medicines.

Further information, including a roadmap for the review, is available on the European Commission’s website\(^{32}\).

---


2. SME INITIATIVE
2. SME Initiative

2.1. Objective

The primary aim of the SME initiative is to promote innovation and the development of new medicinal products by smaller companies. To achieve this, incentives are provided to help SMEs overcome the main financial and administrative hurdles associated with pre-marketing procedures, particularly scientific advice, marketing authorisation application and inspection procedures. The initiative also introduced incentives for post-authorisation procedures.

2.2. Definition of an SME

In determining which companies are eligible for SME incentives, EMA applies the EU definition of micro, small and medium-sized enterprises provided in Commission recommendation 2003/361/EC. This means that companies are classified according to their category (autonomous, partner or linked) and size (micro, small or medium), as defined below, and in the table on p.17:

- **AUTONOMOUS ENTERPRISE**
  
  My enterprise holds less than 25% (capital or voting rights) in another and/or another holds less than 25% in mine.

  *Note: there are exceptions for certain types of investors. See article 3(2) in the annex of Commission recommendation 2003/361/EC.

- **PARTNER ENTERPRISE**
  
  My enterprise holds at least 25%, but no more than 50% in another and/or another holds at least 25%, but no more than 50%, in mine.

- **LINKED ENTERPRISE**
  
  My enterprise holds more than 50% of the shareholders’ or members’ voting rights in another and/or another holds more than 50% in mine.

Depending on the category in which the enterprise fits, some or all of the headcount and financial data from other partner or linked enterprises may need to be counted when calculating whether the SME criteria are met.

‘The revised user guide to the SME definition’, published by the European Commission, provides further information on the definition of an SME. The user guide is available in a number of EU languages.

2.3. Role of the SME office

The SME office was established at EMA to offer assistance to SMEs who, due to lack of experience with the centralised authorisation procedure or lack of familiarity with the Agency and its procedures, may otherwise experience difficulties with the development and marketing of their new medicinal products. The SME office will facilitate contacts with the relevant scientific and regulatory staff within the Agency to address any questions that may arise during the development of a medical product, particularly in the run up to submitting a marketing authorisation application.

2.4. Incentives for SMEs (EU provisions and national provisions)

2.4.1. Incentives offered by EMA

The EU incentives offered by the Agency apply to both the human and veterinary sectors, and include:

- Regulatory, administrative and procedural assistance from the Agency’s SME office including SME briefing meetings;
- Fee incentives
  - Fee reductions for scientific advice, scientific services, inspections and (for veterinary medicines) establishment of maximum residue limits;
  - Fee exemptions for certain administrative services of EMA;
  - Deferral of the fee payable for an application for marketing authorisation or related inspection;
- Conditional fee exemption where scientific advice is followed and a marketing authorisation application is not successful;

---

Fee reductions and exemptions for post-authorisation procedures\textsuperscript{36}.

Fee reductions and exemptions for pharmacovigilance activities\textsuperscript{37}.

Certification of quality/non-clinical data for advanced therapy medicinal products (ATMPs) intended for human use;

Translations of the product information documents submitted in the application for marketing authorisation;

Waiver of the MedDRA licensing fee when registering with EudraVigilance. This is only available for micro- or small enterprises, not for medium-sized enterprises;

Inclusion in the SME public register.

\textbf{Fee reductions/deferrals}

SMEs operating in the pharmaceutical sector are often innovative companies that can notably benefit from the access to scientific expertise at EU level. The SME initiative has been designed, with a substantial 90% fee reduction for scientific advice, to encourage SMEs to seek advice from EMA on all issues relating to the development of new medicinal products, with a view to maximising the chances of a successful marketing authorisation (see section 3.4).

Other financial incentives include a 90% fee reduction for any good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP), or pharmacovigilance inspections requested by EMA.
and the possibility to request deferred payment of any pre-authorisation inspection fee. For veterinary medicines, there is also the possibility to request a 90% fee reduction for establishment of maximum residue limits. Fee incentives are also offered for administrative services from EMA (e.g. EMA certificates of medicinal products, ‘article 58’ scientific opinions for human products intended exclusively for markets outside the EU).

In the run up to filing an application for marketing authorisation, the fee payable to EMA for review of the application may place financial constraints on smaller companies. For SMEs, fee payment may be deferred by up to 45 days after the date of notification of the centralised marketing authorisation, or, in the event of withdrawal of the application, within 45 days from the date of notification of withdrawal. In the event of a negative outcome, where scientific advice has previously been sought from EMA and taken into account in the development of the medicinal product, the fee for the application for marketing authorisation will be fully waived by the Agency.

Fee incentives also apply for post-authorisation procedures for centrally authorised products and pharmacovigilance activities for all products irrespective of the authorisation route. For post-authorisation incentives, full fee exemptions apply for micro-sized enterprises and a 40% fee reduction for small or medium-sized enterprises.

Access to incentives

Access to the fee reductions and deferrals outlined above will be subject to the applicant company’s SME status being assigned by EMA and remaining valid on the date that the fee falls due for the relevant application or procedure (see section 2.5). The financial incentives will not be applied retrospectively.

If a product is out-licensed to another company during a procedure, the SME office at EMA should be informed immediately. If the company licensing in the product does not meet the SME criteria, there will be no further access to the provisions of the SME Regulation with effect from the date of the licensing agreement. Any fees shall no longer be subject to fee deferral pursuant to the SME Regulation.

For pharmacovigilance activities, access to the fee incentives will be subject to the applicant company’s SME status being assigned by EMA or will be based on the submitted SME declaration.

Further information on fee incentives is available in the document 'Explanatory note on fees payable to the European Medicines Agency' and in the 'Explanatory note on pharmacovigilance fees payable to the European Medicines Agency'.

Certification of advanced therapy medicinal products

Advanced therapy medicinal products (ATMPs) are often developed by SMEs. As an incentive to develop such products, an SME can submit to EMA, the results of studies carried out to demonstrate the quality and non-clinical safety of ATMPs and request evaluation and certification of the data, independently of any MAA. Although not legally binding, the certification procedure should facilitate the evaluation of any future application for clinical trials and marketing authorisation based on the same data (see section 3.3.2 for information on certification).

Translation of product information

Translating product information into all EU languages represents a considerable financial and administrative burden to SMEs entering the EU market. Thus, EMA provides translations of product information (summary of product characteristics, label, package leaflet and relevant opinion annexes) required to grant an EU marketing authorisation. Translation into EU official languages are provided free of charge by the Agency.

Due to the timelines required to translate the product information, the Agency initiates translations through the centre for translation (CdT) in Luxembourg at the time of CHMP/CVMP opinion. These translations are then checked through the national competent authorities in the Member States. To be eligible for translation assistance, the company’s SME status must be valid at the time that the translations are initiated. It is the responsibility of the applicant SME to provide Norwegian and Icelandic translations.

Practical details are sent to the applicant, together with the translations timetable, prior to the opinion.

SME briefing meetings

Small enterprises with limited resources often lack experience or are unfamiliar with the regulatory approval process.

Opening up early dialogue with EMA during development, such as scientific advice and during the pre-submission phase of marketing authorisation application, can be challenging for SMEs, which may have limited capacity or experience to navigate the regulatory landscape for pharmaceuticals.

The SME office offers SME briefing meetings, which provide a platform for a company to discuss its planned regulatory strategy. SMEs are encouraged to approach the SME office to request a briefing meeting at any stage of their product development.

SME briefing meetings are provided free of charge by EMA.

2.4.2. Other EU incentives for SMEs

Further information on the whole spectrum of EU policies, legislation, programmes and initiatives relevant to Europe’s SMEs is available from the European Commission through its European portal for SMEs40.

An overview of initiatives to support financing of SMEs (EMA/986534/2011)41 and research funding opportunities (EMA/748291/2014)42 from the European Commission have been published on the EMA website43.

Detailed information on the EU financial support available to SMEs can also be accessed via a single access point on EU finance44.

2.4.3. National provisions for SMEs

Commission Regulation (EC) No 2049/2005 requires the SME user guide to reference existing national provisions for SMEs, applicable to the pharmaceutical sector. These are provided in annex 1.

If companies have a query relating to any existing national provision and would like to contact the national competent authority in question, contact points are also provided in annex 1.

2.5. How to request SME status

2.5.1. Assignment of SME status

Companies wishing to benefit from SME incentives should visit the SME office section of EMA website45 first. Before requesting financial or administrative assistance from the Agency, companies should complete the form ‘Declaration on the qualification of an enterprise as a micro, small or medium-sized enterprise (SME)’46. This should be submitted to the SME office, together with the most recent annual accounts (audited, if possible) for the applicant enterprise and any linked or partner enterprise, the proof of establishment of the organisation in the EEA (i.e. an EU Member State, Iceland, Liechtenstein or Norway), and details of upstream (i.e. owners of your enterprise’s shares or voting rights) and downstream ownership structure (i.e. your enterprise’s participation in other companies in terms of shares or voting rights) in the form of an overview chart of the company structure. Companies are strongly recommended to read ‘The revised user guide to the SME definition’47, published by the European Commission, before completing the form. It is particularly useful in helping to determine whether the applicant company is an autonomous, partner or linked enterprise, and whether it is necessary to complete the annexes to the declaration form.

If the documentation appears to be in order and no clarification is required, EMA will issue the enterprise with an EMA-SME number. At that point the company may request access to the incentives offered by the SME Regulation. The Agency reserves the right to request further information from the company to establish that the SME criteria are met and may, at any time, perform audits as part of its SME programme. The applicant enterprise will be liable to consequences in case of a false declaration.

40) http://ec.europa.eu/small-business/index_en.htm
44) http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000063.jsp&mid=W0b01ac0580024b9a
45) http://access2eufinance.ec.europa.eu
2. SME INITIATIVE

2.5.2. Newly established or non-EEA enterprises

If your enterprise is newly established and does not have finalised financial reports, estimates should be provided for the reference period declared together with an indication of when the first annual accounts will be available.

For non-EEA companies, there are essentially two options to access SME incentives:

- to apply once the company has established a subsidiary in the EEA. For proof of establishment, the SME office requires a copy of the certificate of incorporation in the company’s commercial register. In such cases, the SME declaration can be submitted in the name of the newly established subsidiary with details of the parent company as a ‘linked’ enterprise, if applicable, or
- to indirectly benefit from the SME incentives through an EU established SME regulatory consultancy.

SME regulatory consultancies may seek to benefit from the provisions of the SME Regulation on behalf of non-EEA based clients only if both they and the client meet the SME criteria (i.e. fall below headcount and financial thresholds). In this case, both the regulatory consultant and the non-EEA based company should submit SME declarations. If successful, the regulatory consultant would receive an SME notification and the non-EEA based company would be listed in annex to that notification as an SME client company. It is not possible for an SME regulatory consultant to be considered eligible if they are acting on behalf of non-SME clients, as this would be contrary to the objectives of the SME Regulation.

2.5.3. Maintenance of SME status

A company’s SME status expires two years after the date of closure of the accounts on which the declaration has been based. In order to extend SME status, companies are advised to submit via e-mail an updated SME declaration form for the company based on the latest approved accounts.

It is only necessary to submit supporting accounts and ownership data where one of the following applies:

- change in the type of the enterprise (autonomous, partner, linked) or significant changes in the upstream or downstream ownership structure (e.g. acquisition, takeover, merger of the applicant and its partner/linked entities);
- SME thresholds exceeded over one accounting period\(^48\);
- the company’s previous submission was based on a bona fide estimate of the headcount and financial data;
- the company’s SME status has expired and there are one or more years of accounting data missing since the last submission.

EMA will send out individual reminders for renewal prior to SME status expiry.

In the event that a registered SME is acquired by or merges with another company, the SME office at EMA should be informed immediately. If the SME criteria are no longer met by the newly formed company, then with effect from the date of the change in ownership, the company will have no further access to the provisions of the SME Regulation.

\(^{48}\) Article 4.2 in the annex to Commission Recommendation 2003/361/EC
3. SUPPORT TO MEDICINAL PRODUCT DEVELOPMENT
3. SUPPORT TO MEDICINAL PRODUCT DEVELOPMENT

3. Support to medicinal product development

3.1. Innovation task force (ITF)

For sponsors developing innovative medicines (e.g. advanced therapies), new technologies (e.g. nanotechnologies, e-Health), and new scientific approaches (e.g. non-clinical methods and models, biomarkers, -omics, synthetic biology, assay [co-]development, modelling & simulation or novel clinical trial methodology), the innovation task force (ITF) provides a platform to open up an informal dialogue with the Agency for both human and veterinary products.

SMEs can approach the ITF and proactively identify scientific, legal and regulatory issues arising from their developments. The scientific discussions are led by experts from the EU network, the Agency’s working parties and committees, where the best available scientific expertise is represented.

Borderline medicinal products are also included in the scope of the ITF.

The meetings are free of charge and aim to facilitate the informal exchange of information and guidance in the development process, complementing and reinforcing existing formal procedures (e.g. scientific advice, ATMP certification).

Further information on how to contact the ITF, including forms for requesting briefing meetings, is available on the EMA website49. General queries can be sent to ITFsecretariat@ema.europa.eu.

Further information on the PRIME scheme, including detailed information on how to apply, is available on the EMA website50. General queries can be sent to prime@ema.europa.eu.

For innovative veterinary medicinal products, queries can be sent to: vet.applications@ema.europa.eu.

3.2. PRIority MEdicines (PRIME) scheme (human medicines only)

PRIME (PRIority MEdicines) is a voluntary scheme to support the development of new medicines for human use that address an unmet medical need and facilitate their timely access to patients. The scheme focuses on medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients with no treatment options. The scheme is limited to products under development and yet to be placed on the EU market.

The scheme provides enhanced scientific and regulatory support through key features:

- early confirmation of medicines with a potential for accelerated assessment at the time of marketing authorisation application (see also 6.14.1);
- early selection of a rapporteur from the scientific committees (see also 6.2);
- dedicated meeting with the rapporteur and experts to provide guidance on the overall development plan and regulatory strategy;
- scientific advice at development milestones, involving stakeholders such as health-technology-assessment bodies and patients as applicable (see also 3.4);
- eligibility to additional SME fee reductions for scientific advice.

PRIME is open to sponsors on the basis of preliminary clinical evidence. SMEs and applicants from the academic sector can apply earlier on the basis of compelling non-clinical data and tolerability data from initial clinical trials.

Further information on the PRIME scheme, including detailed information on how to apply, is available on the EMA website50. General queries can be sent to prime@ema.europa.eu.

3.3. Advanced therapy medicinal products (ATMPs)

This section applies to medicinal product for human use only.

3.3.1. Classification procedure as an ATMP

Advanced therapy medicinal products (ATMPs) are defined in legislation51 as gene therapy, somatic cell therapy and human tissue engineering.

Sponsors requiring clarification as to whether their product is classified as an ATMP can receive confirmation from the committee for advanced therapies (CAT) prior to submitting any application to the Agency. This advice is provided free of charge within 60 days of receipt of a valid request from an applicant. The Agency publishes summaries of these recommendations after deletion of all information of a commercially confidential nature.

---

For more information SMEs are advised to refer to the procedural advice on classification as an ATMP (EMA/CAT/99623/2009 Rev.1).32

### 3.3.2. Certification for ATMPs

The certification procedure for ATMPs, which is open exclusively to SMEs, provides a mechanism for companies to receive scientific feedback on quality and non-clinical data generated during the course of development. As such, it provides support for companies seeking to attract investors for the development of their product or to license it out.

Through certification, companies can receive an evaluation of their data according to the current review standards for marketing authorisation. Certification is complementary to the scientific advice process (see section 3.4). Whereas scientific advice provides feedback on future development proposals and protocols, certification provides a scientific evaluation of experimental data already generated with the product. Companies can then seek scientific advice on how to resolve any deficiencies that may have been highlighted during the certification assessment.

An SME can submit an application for certification containing either quality data alone or both quality and non-clinical data at any time during the development of an ATMP. The process can be repeated as development proceeds. The procedure for certification consists of a 90 day review by the CAT with the possibility to request clarifications.

For more information SMEs are advised to refer to the procedural advice53 and guidance54 on the EMA website. Any queries can be sent to: AdvancedTherapies@ema.europa.eu.

### 3.4. Scientific advice/protocol assistance

At any stage of development, and irrespective of eligibility to use the centralised procedure for marketing authorisation, sponsors can request scientific advice from EMA for both human and veterinary medicinal products. SMEs are particularly encouraged to initiate an early dialogue with the Agency, in the form of scientific advice. This helps the sponsor to ensure that the appropriate tests and studies are performed, so that no major objections regarding the design of the tests are raised during evaluation of the marketing authorisation application. Such major objections can significantly delay the marketing of a product, and in certain cases may result in refusal of the marketing authorisation. Following the Agency’s advice therefore increases the probability of a positive outcome.

For human medicinal products, scientific advice is given by the EMA’s committee for medicinal products for human use (CHMP) on the recommendation of the scientific advice working party (SAWP-H). For veterinary products, it is given by the committee for medicinal products for veterinary use (CVMP) on the recommendation of the veterinary equivalent, the SAWP-V. Both scientific advice working parties have monthly meetings.

Guidance on how to put together a request for scientific advice for human medicinal products55 and veterinary medicinal products56, including detailed information on how to apply, templates for notifying intent of submission and submission deadlines, is available on the Agency’s website.

The Agency offers assistance to applicants in putting their scientific advice requests together through free pre-submission meetings. SMEs are strongly recommended to request a pre-submission meeting or teleconference at the time they notify their intent to file the request.

Scientific advice is restricted to purely scientific issues. Regulatory requests should be the subject of separate advice from EMA and can be sent to the SME office.

#### 3.4.1. Scope of scientific advice

Scientific advice may be sought on the tests required to support an application for marketing authorisation for a medicinal product (see sections 4.1-4.3 and sections 5.1-5.5) in the areas of:

- quality (chemical, pharmaceutical and biological testing);
- non-clinical/safety (toxicological and pharmacological tests);
- clinical aspects (clinical safety and efficacy; conditional marketing authorisation; post-authorisation efficacy/safety studies);
- data requirements for minor use minor species (MUMS) products in line with the published MUMS guidelines;

---

3. SUPPORT TO MEDICINAL PRODUCT DEVELOPMENT

- the establishment of new Maximum Residue Limits (MRLs) or extrapolation of existing MRLs for veterinary medicinal products.

Scientific advice for designated orphan medicinal products (applies to medicinal products for human use only. See section 4.4) is called ‘protocol assistance’ and, in addition to the above, may include questions relating to:

- demonstration of significant benefit within the scope of the designated orphan indication;
- issues addressing similarity/clinical superiority in case other potentially similar orphan medicinal products have market exclusivity in the concerned therapeutic indication.

Guidance on how to seek protocol assistance for designated orphan medicinal products is available on the EMA website.

It is also now possible for sponsors to approach EMA and National Health Technology Assessment bodies in parallel to discuss scientific advice/protocol assistance. HTAs provide information to decision makers about the clinical and cost effectiveness of medicines, medical technologies and health systems. Many EU Member States have established HTA systems to support decision makers in pricing and reimbursement decisions. Sponsors considering such parallel requests are advised to contact the scientific advice secretariat (scientificadvice@ema.europa.eu).

For veterinary medicinal products, scientific advice requests may include questions relating to limited markets (including MUMS applications). Sponsors may request scientific advice on the data requirements for MUMS products in line with the MUMS guidelines on a case by case basis (see section 5.7).

Sponsors that are intending to seek scientific advice for either human or veterinary products in the EU and the US may consider asking for parallel EMA-FDA scientific advice57. In this case, the application is evaluated by both agencies at the same time and the EU and US experts discuss together with a view to reaching the same conclusions.

**Novel methodologies**

Sponsors can also request advice from EMA on innovative methods or drug development tools for medicinal products for human use through a voluntary qualification process58:

- qualification advice on future protocols and methods for further method development towards qualification, based on the evaluation of the scientific rationale and on preliminary data submitted;
- qualification opinion on the acceptability of a specific use of the proposed method (e.g. use of a biomarker) in a research and development (R&D) context (non-clinical or clinical studies), based on the assessment of submitted data.

3.4.2. Fee reductions for scientific advice

The scientific advice procedure attracts a fee, which varies depending on the scope of the advice. This may deter some companies from seeking advice early on in development, or from making several successive requests. Therefore, access to the Agency’s scientific advice has been facilitated for SMEs by a substantial 90% fee reduction. Furthermore, as the scientific evaluation of a marketing authorisation application is more likely to be favourable where scientific advice has been sought from the Agency, in the event of a negative outcome, a conditional exemption of the fee for the application for marketing authorisation will be given to applicants who have requested such advice and who have actually taken it into account in the development of their medicinal product.

Further information on the level of fee reductions/deferrals available to SME applicants is available in the document ‘Explanatory note on fees payable to the European Medicines Agency’59.

Scientific advice is free of charge for designated orphan medicinal products (or so-called protocol assistance), paediatric developments and medicines qualified through the PRIME scheme.

---

In order to support the research and development of veterinary medicinal products for minor species and for rare indications in animals, a policy on minor use minor species (MUMS)/limited market has been established by the Agency (see section 5.7). For products classified by the CVMP as MUMS/limited market with financial incentives in accordance with the established CVMP criteria scientific advice is provided free of charge. All applicants for products classified as MUMS/limited market are strongly encouraged to seek scientific advice on the data requirements and application of the CVMP MUMS guidelines on quality, safety, efficacy or immunologicals for veterinary medicinal products.

3.5. Scientific guidelines and position papers

Scientific guidelines for human and veterinary medicinal products are available on the EMA website.

Documents which do not fall under the heading of scientific guidelines, such as historical position papers, question-and-answer documents, or general regulatory guidelines can be found on the:

**EMA website:**
under ‘regulatory and procedural guidance’ on the ‘human medicines’ page or for ‘veterinary medicines’ under ‘general guidance’.

**European Commission website:**
in the notice to applicants, vol. 2C and 6C – regulatory guidelines.

---

4. MEDICINAL PRODUCT DEVELOPMENT (HUMAN)
4. Medicinal product development (human)

The data requirements for an application for marketing authorisation for a human medicinal product are laid down in EU legislation, in particular annex I of Directive 2001/83/EC (see sections 1.2). Guidance is available in the scientific guidelines adopted at ICH and EU levels, and in the notice to applicants (NTA)\(^{62}\) which includes guidance on the common technical document (CTD) (see section 6.6).

An overview of the pharmaceutical, non-clinical and clinical development of a medicinal product for human use is provided in sections 4.1-4.3 below. For detailed information, SME companies should consult EMA website where all current scientific guidelines are published (see section 3.5).

The SME office monitors applications for marketing authorisation (MAA) submitted to the Agency by SMEs and reports annually on the outcomes\(^{63}\). The success rate of SMEs has improved over the last years but still lags behind the average for all applicants. The need for additional clinical data (module 5) to support the applications is one of the main reasons for refusal or withdrawal of the MAAs. The quality documentation (module 3) has also been found to be a particular problem area for many SMEs.

To ensure that the appropriate studies are performed and that there are no major objections regarding the study design at the time of the evaluation of the marketing authorisation application, SMEs are particularly encouraged to seek scientific advice from EMA (see section 3.4). The importance of opening up an early dialogue with the Agency on all aspects of development, including quality, is underlined.

Figure 1 provides an overview of the various opportunities for dialogue offered to SMEs throughout the development of a medicinal product.

4.1. Quality

The pharmaceutical quality of a medicinal product (human or veterinary) consists of two main pillars:

The purpose of the pharmaceutical development is to develop a formulation that will be fit for its intended use, that is, to consistently deliver the active substance at the site of action at the required dose and that will be stable throughout its shelf-life.

4.1.1. Active substance (drug substance)

An active substance means a substance with physiological or pharmacological activity, which is responsible for the claimed clinical effect of the product, be it therapeutic, prophylactic or diagnostic. Depending on their source, active substances can be classified as inorganic substances, herbal substances and herbal preparations, ‘chemical’ (synthetic or semi-synthetic, or isolated and purified from herbal sources or microorganisms) and biological active substances.

The amount of information to be generated during development depends on whether the active substance is a new substance, being used for the first time in a medicinal product in the EU, or an existing active substance (either described in a pharmacopoeia, or not). However in all cases the active substance should be well characterised and manufactured by well-described and adequately controlled manufacturing methods (see section 4.6.1).

For new active substances, applicants are encouraged to apply for an international non-proprietary name (INN) as early as possible in the clinical development. INNs are assigned by the WHO\(^{64}\), to whom requests should be submitted.

When developing a medicinal product, the following key issues should be addressed with regards to active substances:

\(^{63}\) http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000063.jsp&mid=WC0b01ac0580024b9a
\(^{64}\) http://www.who.int/medicines/services/inn/en/
Figure 1 - Overview of medicinal products development, incentives and opportunities for dialogue with EMA
4. MEDICAL PRODUCTS DEVELOPMENT (HUMAN)

General information: Structural formula, including relative and absolute stereochemistry, molecular formula, and relative molecular mass. Examples of physico-chemical and biological properties that might need to be examined include solubility, water content, particle size, crystal properties, biological activity, and permeability. The solid-state properties that might affect the in vivo performance are of particular importance. Additionally for proteinaceous biological active substances the schematic amino acid sequence indicating glycosylation sites or other post-translational modifications and biological activity should be available.

Manufacture: The manufacturing process should be well described and understood. All critical parameters should be identified and appropriately controlled. It should also be demonstrated that the process can reproducibly produce a substance with the desired quality characteristics. In addition to the starting materials, that is all the materials from which the active substance is manufactured, should be evaluated and documented.

Biological active substances are often generated by cell substrates (microbial cells or cell lines derived from human or animal sources that possess the full potential for generation of the active substance). For cell substrates having a cell banking system, all procedures to generate the master cell bank and the working cell bank(s) should be documented. Characterisation and testing of banked cell substrates should be carried out to confirm their identity, purity, stability and suitability for manufacturing use. Particular attention should be given to potential contamination from adventitious agents (see section 4.1.3).

When there is a change in the manufacturing process of a chemical or biological active substance, it should be ensured that it will not affect the product. For biological active substances in particular, consideration should be given to performing a comparability exercise. If the analytical data are not sufficiently reassuring, additional evidence from bridging non-clinical and clinical studies will be required.

Characterisation: Extensive characterisation is performed in the development phase and, where necessary, following significant process changes. Characterisation is necessary to allow relevant specifications to be established.

The potential for isomerism, identification of stereochemistry, and polymorphism should be evaluated. The purity of a substance is often judged by examining the impurities it contains. Therefore special emphasis should be given to characterising the impurities which arise from the method of manufacture and also those produced on storage, by degradation. Similarly, how impurities are generated should be described. If the level of impurities exceeds certain thresholds specified in the (V)ICH guidelines on impurities65, their toxicological significance becomes important from a safety point of view. Therefore these impurities have to be 'qualified' (usually with reference to formal toxicology studies) to demonstrate they are safe.

Control of active substance: Specifications are critical quality standards that are based on thorough characterisation and on the mechanistic understanding of how formulation and process factors can impact product performance. Specifications should reflect the characteristics an active substance should have to meet its intended purpose. Conformity with specifications should provide assurance that quality is maintained from the time of release to the end of the shelf-life/re-test period. The acceptance criteria should be established and justified based on data obtained during development, including manufacturing consistency studies, stability studies and lots used in non-clinical and/or clinical studies. The analytical procedures that will be used to test the critical-to-quality attributes should be adequately validated in accordance with (V)ICH guidelines.

Stability: The applicant should study how the quality of the active substance varies with time under the influence of a variety of environmental factors such as temperature, humidity and light. This will allow the definition of practical storage conditions and a 'window of use' called the shelf-life/re-test period (during which the substance may be used without further testing).

Submission of information for active substances: There are three ways to present the information relating to the active substance in a marketing authorisation application:

- Full data is presented in the dossier.
- Active Substance Master File (ASMF): An ASMF contains all the necessary information on the active substance and is composed of two separate sections. The "applicant’s part" contains the majority of the information (non-confidential) and is available to the applicant. However, in the "restricted part" the active substance manufacturer can submit detailed information relating to the manufacturing process, controls and validation and this is submitted directly to the competent authorities in order to protect the manufacturer’s intellectual property. The concept of the ASMF applies only to "well-defined active substances". It therefore cannot be used for biological active substances, excipients, finished products, container materials, etc.

Certificate of suitability (CEP): The manufacturer of the active substance may apply to the Certification of Substances Division (DCEP) of the EDQM\textsuperscript{66} with documentation requesting evaluation of the suitability of the relevant Ph. Eur. monograph for the control of the chemical purity and microbiological quality of their active substance. If a CEP is available from the active substance manufacturer, reference to this is made in the application and no additional information needs to be submitted for those parts of the dossier covered by the CEP. However, additional information might be necessary depending on how the attributes of the active substance affect the finished product performance, for example, particle size, sterility, etc. Manufacturers or suppliers of excipients, herbal substances and preparations used in the production or preparation of pharmaceutical products or any product with transmissible spongiform encephalopathy (TSE) risk, may also choose to apply for a CEP.

4.1.2. Finished product (drug product)

The key issues that applicants should address during the development of the finished product are summarised below:

Formulation development: When developing a formulation it is important to identify attributes that are critical to the quality of the finished product, taking into consideration its intended usage, route of administration and the specific needs of the intended patient population (for example, paediatrics or the elderly).

The choice of all the excipients should be justified. Although excipients are usually inactive substances, their safety for the target population (for example, paediatric population or the target animal species) should be considered.

The potential effect of the physicochemical properties of the active substance (for example, water content, solubility, particle size distribution, polymorphic or solid state form) on the performance of the finished product should be evaluated. Other key issues to be investigated are the compatibility of the active substance with the excipients, containers and closures. For combination products, the compatibility of active substances with each other should also be evaluated.

It is highly likely that during the product’s development there will be changes in the formulation and manufacturing process. In all cases the differences between the clinical formulations used and the formulation intended to be marketed should be discussed and their equivalence demonstrated (using either in vitro or comparative in vivo studies, as appropriate).

If the formulation contains a novel excipient, that is, an excipient used for the first time in an EU-authorised medicinal product, or by a new route of administration, then full details of its manufacture, characterisation and control, with cross references to supporting safety data (non-clinical/safety and/or clinical) should be provided. As there can be no confidential master file for excipients, applicants should provide all such information in the application for marketing authorisation.

Microbiological attributes: All parameters relevant to the microbiological attributes of the dosage form should be evaluated. Examples include the selection and effectiveness of preservative systems in products containing antimicrobial preservatives, and, for sterile products, selection and description of the sterilisation process and the integrity of the container/closure system for prevention of microbial contamination. The compatibility of the drug product with reconstitution diluent(s) or dosage devices (e.g. precipitation of drug substance in solution, sorption on injection vessels, stability) should also be demonstrated.

Process development: It is important to consider the critical formulation attributes, together with the manufacturing process options, in order to address the selection of the manufacturing process and confirm the appropriateness of its components. The manufacturer must have adequate knowledge of the manufacturing process in order to ensure that material and process variability is adequately understood and managed. In general, process development studies should provide the basis for process improvement, process validation and continuous process verification. In some cases, e.g., for complex products, the applicant may decide to perform enhanced development studies over a wider range of material attributes, manufacturing process options and process parameters. These studies coupled with the use of statistical experimental design techniques, risk management principles and on-line, in-line or at-line analytical methods may lead to a better understanding of the process and the product. Such studies may be used to support real time release testing and more flexible regulatory approaches in setting the operational limits of the process as well as potential process changes during the lifecycle of the product. For manufacturing process changes for biological/biotechnological products, the same recommendations as mentioned above (for active substances) apply.

Manufacture, control of excipients and the finished product, and stability: As with active substances, the manufacturing process used for the finished product should be carefully designed so that it consistently produces product of the intended quality. All critical steps should be identified and controlled with appropriate...
in-process controls. Batch-to-batch consistency must be demonstrated using appropriate process validation studies. The usual process validation approach is to manufacture a number of production scale batches to confirm that the process is under control. For non-standard processes (e.g. manufacture of specialised dosage forms, or use of new/highly specialised technologies, as well as non-standard sterilisation methods) the validation data usually need to be provided with the submission. For all other processes these data may be generated in accordance with approved protocols once production starts. It is also possible to follow other validation approaches, e.g., a continuous process verification scheme, provided that this is appropriately justified and supported by adequate development studies.

Appropriate specifications should be set for the excipients and the finished product and validated methods should be used for their testing.

The stability of the finished product should be demonstrated throughout its proposed shelf-life under the proposed storage conditions. The stability studies should be performed in accordance with the (V)ICH recommendations (e.g. storage conditions, duration) unless otherwise justified. For multiple dose containers, the proposed in-use shelf-life should be similarly demonstrated. In all cases, the analytical methods that are used to test the product should be stability indicating.

4.1.3. Other specific issues

Adventitious agents: All materials of human or animal origin used in the manufacturing processes of either the active substance or the finished product, or coming into contact with the active substance or finished product during the manufacturing process, should be identified. The risk with respect to potential contamination with adventitious agents of human or animal origin should be assessed.

TSE agents: The current “note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products” (EMA/410/01) should be applied. Suppliers of any substances with a TSE risk used in production or preparation of medicinal products can apply to the Ph. Eur. for a TSE certificate. Such certificates can then be used by marketing authorisation applicants (For more information, see the EDQM website).

Viral safety: The risk of introducing viruses into the product and the capacity of the manufacturing process to remove or inactivate viruses should also be evaluated.

Other adventitious agents: Detailed information regarding other adventitious agents, such as bacteria, mycoplasma and fungi should be provided.

4.2. Non-clinical development

The non-clinical development consists of three main parts:

1. Pharmacology
2. Pharmacokinetics & Metabolism
3. Toxicology

The purpose of non-clinical development is to evaluate the pharmacodynamic and toxicity profile by the clinical route of administration prior to initiating clinical studies, to predict potential safety problems at a given exposure and to investigate particular safety aspects as detailed below.

Some of the non-clinical studies need to be performed before administration of first dose to man while others can run in parallel to clinical trials (see figure 1). The summary below outlines the important tests generally required; for comprehensive details please refer to the relevant scientific guidelines (section 3.5). ICH M3(R2) and CHMP guidance on first-in-human clinical trials (EMA/CHMP/SWP/28367/07) provide guidance on the non-clinical safety studies required for the conduct of clinical trials.

---

68) https://www.edqm.eu/en
4.2.1. Pharmacology

This part of the development addresses the pharmacodynamics of a new product in the non-clinical setting.

The pharmacodynamics includes investigation of "primary" pharmacodynamics, which comprises in vitro and in vivo effects related to the proposed therapeutic indication. There are many established animal models for various conditions. If there are no models available, sponsors should investigate the added value of developing a relevant model. Moreover several novel products react only with human epitopes which may be different in experimental animals. In this case sponsors may consider developing a homologous product which would react with the animal epitope or develop transgene animal models. In addition, investigation of the "secondary" pharmacodynamics (effects other than those related to the proposed therapeutic indications) is required. Safety pharmacology addresses undesired pharmacodynamic effects on specific physiological systems. The minimum safety pharmacology requirements are the core battery exploring the vital functions of the central nervous, cardiovascular and respiratory systems in relation to exposure in the therapeutic range and above, generally after a single dose administration. ICH S7A & S7B provide guidance71.

Finally it is necessary to investigate pharmacodynamic drug interactions with medicinal products that are likely to be administered for the same condition.

4.2.2. Pharmacokinetics & Metabolism

This part of the development comprises studies investigating the absorption, excretion, tissue distribution, metabolism and pharmacokinetic drug interactions. The area under the matrix level concentration-time curve (AUC), Cmax at the expected peak concentration and C (time) at certain time points after administration are the most commonly used parameters in assessing exposure in pharmacokinetics studies. Other parameters include urinary & faecal excretion, bioavailability, half-life, fraction of unbound drug, volume of distribution and tissue distribution. Metabolism is important to consider in the evaluation of the relevance of toxicity for humans. In vitro models (e.g. hepatocytes in culture) comparing the metabolic profile between animal species and humans contribute to the choice of the most relevant animal species to support clinical trials.

4.2.3. Toxicology & Toxicokinetics

The following studies should generally be performed during the development:

Single and repeated dose toxicity: The primary goal is to characterise the toxicological profile of the medicinal product following repeated daily administrations. This includes identification of target organs of toxicity, determination of a No Adverse Effect Level (NOAEL), exposure response relationship and potential reversibility of toxic effects. Unless justified, experiments in two species are required, one of which should be non-rodent and the duration depends upon the planned human use. Single dose toxicity studies are not required unless this is the planned clinical utility. For products for chronic use in humans, repeated dose toxicity studies of at least six months duration are requested (ICH M3). In addition to investigating toxicity, kinetic parameters, in particular exposure (AUC) should be investigated in the pivotal repeated-dose toxicity studies (toxicokinetics). Toxicokinetics provide a means of obtaining multiple dose pharmacokinetic data in the test species in the range of doses used in toxicology; the ratio of AUCs in humans and at the NOAEL in animals allows the calculation of a safety margin (see ICH S3A & S3B for further guidance72).

Reproductive toxicity: The primary goal is to investigate the effects of the medicinal product on the following steps of reproduction:

- male and female fertility and early embryonic development (to implantation) in one species, usually rats;
- embryo foetal development (development of organs during pregnancy) and toxicity in two species, one of which should be a non-rodent (usually rabbit);
- prenatal and postnatal development in one species, usually rats.

Juvenile toxicity: For medicinal products intended for paediatric use, possible effects of the product on the ongoing developmental processes in the age group(s) to be treated are taken into consideration. In some instances, studies in juvenile animals are required to allow benefit/risk assessment in these patient populations. Juvenile animal studies should be considered to investigate findings that cannot be adequately, ethically, and safely assessed in paediatric clinical trials. Serious adverse reactions that may be irreversible are of particular concern. The design of non-clinical studies in juvenile animals will vary depending on the findings observed in adult human studies and previous animal studies. Even if adverse reactions on developing organ(s) can be predicted from adult human or animal data, studies in juvenile animals might be warranted if there is a need to further address a specific concern for the paediatric population or to establish safety factors. The CHMP guideline on non-clinical testing in juvenile animals (EMA/CHMP/SWP/169215/2005) provides recommendations on such studies (see section 4.5). Furthermore, requirements on the development of paediatric medicines are under discussion at ICH level.

Genotoxicity: Genotoxicity tests are in vitro and in vivo tests designed to detect compounds which induce genetic damage in the DNA directly or indirectly by various mechanisms. The standard battery comprises tests for genotoxicity in bacteria (Ames test), as well as in vitro tests for genotoxicity in mammalian cells and in vivo test for chromosomal damage (micronucleus test usually in the mouse). Compounds which are genotoxic have the potential to induce cancer and/or heritable defects. Genotoxicity test are required for any product, with the exception of most biological products (see ICH S2(R1) for further guidance).

Carcinogenicity: The objectives of carcinogenicity studies are to identify tumorigenic potential in animals and to assess the relevant risk in humans. They are required for pharmaceuticals expected to be administered regularly over a period of at least 6 months and for pharmaceuticals used frequently in an intermittent manner in the treatment of chronic or recurrent conditions. For pharmaceuticals administered infrequently or for a short duration of exposure (e.g. anaesthetics and radiolabelled imaging agents) carcinogenicity studies are not needed unless there is cause for concern. For antitumour medicinal products carcinogenicity studies are normally also not required (see ICH S9).

The carcinogenicity battery consists of two long-term (2-year) studies in the rat and mouse or one long-term study in the rat and one short-term study (6-months) in a transgenic model (see ICH S1A, S1B and S1C).

Immunotoxicity: In the context of medicinal product development, it is defined as unintended immunosuppression or enhancement. All new human pharmaceuticals should be evaluated for the potential to produce immunotoxicity. Methods include evaluating parameters of the immune system in the standard repeated dose toxicity studies mentioned above and additional immunotoxicity studies conducted, as appropriate, if there is cause for concern. In case additional specific immunotoxicity studies are required, a generally accepted study design in rodents is a 28-day study with consecutive daily dosing. Endpoints can include functional tests, such as T-cell dependent antibody response, as well as immunophenotyping of leucocyte populations.

Local tolerance: The purpose of these studies is to investigate whether pharmaceuticals are tolerated at sites of the body that may come into contact with the product as a result of its administration in clinical use. Usually one species is required for each type of test (e.g. ocular tolerance and skin toxicity in the rabbit) and the route of administration is guided by the envisaged clinical use. The local tolerance can be specifically evaluated as part of the repeated dose toxicity study or as a specific study (usually single or repeated administration over a number of days).

Phototoxicity: If a significant potential human phototoxicity risk is identified based on all available data, non-clinical (and clinical) experimental evaluation should be undertaken (see ICH M3(R2) and ICH S10).

Environmental risk assessment (ERA): The purpose of ERA, which is required for all medicinal products, is to investigate the potential environmental risk of the medicinal product following its use in patients. This evaluation is a stepwise approach. The first part of the investigation estimates the exposure of the environment to the active substance and the potential for bioaccumulation and persistence in the environment. Based on an action limit, the assessment of environmental risk may be terminated at this stage. Above this limit, the fate of the substance in and the effects on the environment should be investigated in a second phase.
of investigation. The required tests for fate and effects in the environment include a chronic toxicity study in fish, and tests in daphnia and algae to determine a predicted no-effect concentration. If there are concerns further tests may be required. The CHMP guideline (EMEA/CHMP/SWP/4447/00) and a Q&A document (EMEA/CHMP/SWP/44609/2010 Rev. 1) provide guidance on the testing requirements.

4.3. Clinical development

The purpose of clinical development is to establish a dose-response relationship, demonstrate the efficacy and establish the safety profile of a medicinal product in a therapeutic indication in order to provide an adequate basis for assessing the benefit/risk relationship to support licensing.

Traditionally clinical development has been often described as consisting of four temporal phases: I – IV. Although these terms are not officially used anymore, they are useful to separate the goals of the different stages of the clinical development. The phase concept is a description of the objectives which are summarised below, not a set of requirements. It is also important to realise that the temporal phases do not imply a fixed order of studies since for some medicinal products in a development plan the typical sequence will not be appropriate or necessary. Detailed information is available in the ICH E8 ‘note for guidance on general considerations for clinical trials’ (CPMP/ICH/291/95) and a Q&A document (EMEA/CHMP/SWP/44609/2010 Rev. 1*) provide comprehensive details please refer to the relevant scientific guidelines (section 3.5).

4.3.1. Human pharmacology studies (phase I)

This is the initial administration of a new product into humans. Studies in this phase of development do not aim to assess efficacy and may be conducted in healthy volunteer subjects or certain types of patients e.g. patients with mild hypertension. Due to ethical reasons medicinal products with significant potential toxicity, e.g. cytotoxic compounds used in cancer treatment, are usually studied in patients already in this phase.

The objectives of these studies typically involve one or a combination of the following:

- Using both single and multiple administration of increasing doses, initial safety and tolerability is assessed, which helps guide the dose for future therapeutic trials. Preliminary characterisation of absorption, distribution, metabolism, and excretion (pharmacokinetics) is another goal of these initial studies. For many orally administered medicinal products, especially modified release products, the study of food effects on bioavailability is important. Moreover, depending on the product and the endpoint studied, pharmacodynamic studies and studies relating blood levels of the product to response (PK/PD studies) may be conducted in healthy volunteer subjects or in patients. Pharmacodynamic endpoints may include biochemical or physiological parameters, receptor occupancy etc. Although clinical activity is normally not the goal of this first phase, in some cases data may be collected as a secondary objective; for example, when assessing the pharmacokinetics of a sleeping pill it is possible to obtain some results on potential activity (sleep-inducing effect).

4.3.2. Therapeutic exploratory studies (phase II)

The goal of this phase is to explore therapeutic activity in patients. These studies are typically conducted in a group of patients who are selected by relatively narrow criteria, leading to a relatively homogeneous population. An important goal for this phase is to determine the dose(s) and regimen for the clinical efficacy and safety trials. Early studies in this phase often utilise dose escalation designs (see note for guidance ICH E4) to give an early estimate of dose response, whereby an initial low dose is increased until optimal response or until occurrence of adverse events. The dose response relationship for the indication in question can be confirmed in later parallel dose-response design studies. In this phase, therapeutic activity can be explored using endpoints, which can be evaluated in a shorter time period than the actual therapeutic goal. For example, shrinking of the tumour mass in a particular cancer could be a suitable endpoint to assess activity in phase II, but would normally not be sufficient to demonstrate efficacy in phase III, where “hard” clinical endpoints like survival of the patient would be more relevant. When the results of this phase become available, it is decided if it is justified to proceed to the extensive phase III development.

4.3.3. Clinical efficacy and safety (phase III)

The goal is to confirm the preliminary evidence accumulated in the exploratory stage and to establish efficacy and safety. These studies are intended to provide an adequate basis for establishing benefit/risk ratio and marketing approval. Therefore a sufficiently high number of patients must be enrolled (usually several hundreds to
several thousands) and exposed to the investigational medicinal product for a duration which will provide adequate efficacy and safety data for the envisaged clinical use. Generally for medicines being developed for chronic use studies of at least 6 months duration are required. The studies must generally be controlled, i.e. compare the product under development to placebo (a pharmaceutical preparation containing no active agent, made to look just like the test compound) and/or to active treatment depending on the condition and the product under investigation. In addition the studies must generally be double-blind, i.e. neither the treating physician nor the patient know the treatment administered (test drug, placebo, active comparator). Usually two phase III trials would be required for approval but under specific circumstances one well-conducted large trial may be sufficient. In addition to clinical efficacy, demonstration of safety is the second important goal of this phase. The requirements for investigating the adverse events profile are described in the ICH E 1: 'note for guidance on population exposure: the extent of population exposure to assess clinical safety' (CPMP/ICH/375/95). Generally, 300-600 patients treated for six months and 100 patients exposed for a minimum of one year are considered to constitute an acceptable safety database. However, clinical trials before marketing authorisation have limitations to detect rare adverse events. An event occurring in less than 1/1,000 patients will normally not be detected in the pre-marketing phase.

4.3.4. Therapeutic use/clinical utility (traditionally phase IV)

These are studies related to the approved therapeutic indication which are conducted post marketing. Their goal is to gather additional information about the medicinal products benefits, risks and optimal use in the broad population. Commonly conducted studies include additional drug-drug interaction, safety studies and studies designed to support use under the approved indication, e.g. mortality/morbidity studies, epidemiological studies. Please refer to sections 6.11 and 7.2 for further information on Post-Authorisation Efficacy and Safety (PASS/PAES) studies.

4.3.5. Adaptive designs

Traditionally the protocol of a clinical trial is finalised prior to study start and no changes are allowed during the conduct of the study. In some instances, however, studies can be planned with a so-called adaptive design involving design modifications based on the results of an interim analysis during the study. Such a design has the potential to speed up the process of drug development or can be used to allocate resources more efficiently without lowering scientific and regulatory standards. For further information, refer to the reflection paper on the EMA website.

4.3.6. Clinical trials – notice to applicants

A compilation of legislative and guidance documents in the field of clinical trials, referred to as the 'EudraLex volume 10– clinical trials' has been published by the European Commission and includes guidance on:

- application for starting a clinical trial, to be submitted to the competent authorities of the Member States and the ethics committees;
- guidance on the European clinical trials database (EudraCT database);
- safety monitoring and reporting of adverse reactions arising during clinical trials;
- requirements for manufacturing and import authorisation of investigational medicinal products (IMP);
- qualification of inspectors and inspection procedures;
- the modalities for non-commercial trials;
- recommendation for the trial master file and archiving;
- detailed guidelines on good clinical practice specific to advanced therapy medicinal products;
- clinical trials legislation.

EudraCT

EudraCT is a database of all clinical trials initiated in the EU from 1 May 2004 onwards which was established pursuant to clinical trial Directive 2001/20/EC.

Sponsors should visit the EudraCT website to access the EudraCT application in order to:

- get a EudraCT number;
- submit a clinical trial application form to the competent authorities and ethics committees;
- submit summary of clinical trials results.

---

88) [https://eudraact.ema.europa.eu/](https://eudraact.ema.europa.eu/)
A clinical trial application consists of administrative information and the scientific data necessary for demonstration of the quality, safety and efficacy of the investigational medicinal product (IMP). With regards to the quality of the IMP, it is anticipated that in the early development stages information on the analytical methods, their validation, the setting of specifications and the stability might be incomplete. For this reason, for human medicinal products, different requirements are set for IMPs to be used in phase I, II and III trials. For further information the ‘CHMP Guideline on the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials’ (CHMP/QWP/185401/2004)⁹⁰ should be consulted.

SME companies should be aware that if the final formulation differs from that of the IMP used in earlier clinical trials, the relevance of the earlier material compared to the product tested in later phases should be described. Special consideration should be given to changes in quality parameters with potential clinical relevance e.g. in vitro dissolution rate.

**European clinical trials register**

The EudraCT database was established as a confidential database serving the EEA regulatory authorities. Subsequent changes to the EU pharmaceutical legislation (article 57 of the Regulation (EC) No 726/2004⁹¹ and article 41 of the paediatric Regulation (EC) No 1901/2006⁹²) enabled some of the information held in the EudraCT database to be made public. This information is publicly available through the EU clinical trials register website (EU CTR)⁹².

The information contained in the CTR is extracted from EudraCT. The register allows the public to search for protocol related information and summary of clinical trials results on interventional clinical trials for medicines which are authorised in the EU Member States and EEA and also on clinical trials authorised to be carried out outside of the EU where these trials are part of a paediatric investigation plan.

The guideline and list of fields that are made publicly available are published in chapter V of ‘EudraLex volume 10– clinical trials’⁹³.

The EU CTR has also been recognised as a primary registry of the WHO international clinical trials registry platform (WHO ICTRP)⁹⁴ in September 2011.

**CTFG and voluntary harmonisation procedure (VHP)**

The clinical trial facilitation group (CTFG)⁹⁵ was established during the implementation of clinical trials Directive 2001/20/EC and provides a forum to discuss and agree on common principles and processes to be applied throughout the European medicines regulatory network. It also promotes harmonisation of clinical trial assessment decisions and administrative processes across the national competent authorities (NCAs).

The CTFG has launched a voluntary harmonisation procedure (VHP) for the assessment of multinational clinical trial applications. The procedure has been set up to ensure the protection of participants as well as the scientific value of clinical trials by harmonising NCAs’ processes and practices relating to multinational clinical trials.

The VHP is a tool that may permit applicant companies to achieve through one assessment procedure harmonised and quick approvals of multi-centre clinical trials conducted in several EU Member States. It accepts electronic submissions only and essentially offers sponsors of multinational clinical trials a one-stop-shop for CTAs. Substantial amendments are also included in the VHP.

Further information on how to apply for clinical trial authorisation through the VHP is available in the CTFG “guidance document for a voluntary harmonisation procedure (VHP) for the assessment of multinational clinical trial applications” (CTFG/VHP/2010)⁹⁶.

A list of official contact points of competent authorities⁹⁷ and an overview of the fees⁹⁸ charged by different NCAs for submission of different trial types or amendments has been published by the CTFG.

**Review of EU clinical trials legislation**

Regulation (EC) No 536/2014⁹⁹ (‘Clinical trials Regulation’) simplifies the rules for conducting clinical trials in the EU, aiming to speed up and simplify authorisation
and reporting procedures, while maintaining the highest standards of patient safety and robustness of data (cf. section 1.2.1). The Regulation foresees a coordinated assessment process between the Member States concerned by a trial and the EU database will allow a synchronized submission of the relevant clinical trials documents to all the Member States concerned for a specific trial. Information on clinical trials will be publicly accessible through the EU database, with the exception of the elements for which confidentiality is justified. The new legislative framework entered into force on 16 June 2014 but will become applicable as soon as the EU Portal and EU database will be declared fully operational. The Clinical Trial Regulation indeed requires EMA to develop and maintain a clinical trial portal and database to be used for the submission, authorisation and supervision of trials in the EU.

The following legislations, guidelines, procedures and databases will be updated or replaced accordingly:

- EudraCT database and EU CTR, replaced by the EU database in line with the transitional period set out in Regulation (EC) No 536/2014.
- VHP process phased out in line with implementation of Regulation (EC) No 536/2014.

4.4. Measures for orphan medicines

Orphan designation

‘Orphan’ medicinal products are those intended to diagnose, prevent or treat life-threatening or very serious and debilitating conditions that are rare and affect not more than 5 in 10,000 persons in the European Union.

Incentives

EU incentives available from EMA for sponsors (the pharmaceutical industry developing orphan medicinal products include:

- a 10 year period of market exclusivity after the grant of a marketing authorisation;
- protocol assistance (scientific advice, see section 3.4);
- fee reductions for certain centralised activities;
- direct access to the EMA centralised procedure for the application for marketing authorisation.

To be eligible for orphan incentives medicinal products should be designated through the Community procedure for orphan designation. Orphan designation may be obtained at any stage of development provided a proper scientific justification and data supporting the intended use is submitted. EMA, through its committee for orphan medicinal products (COMP) is responsible for reviewing designation applications and issuing an opinion, which is transformed into a decision by the European Commission.

Guidance on the format and content of applications for designation as orphan medicinal products (ENTR/6283/00) and an application form are available from EMA. The designation procedure attracts no fees. Full details on how to apply (including guidance on calculation and reporting of the prevalence and the elements to support medical plausibility and the assumption of significant benefit) are available on the EMA website.

To facilitate the application process, for those sponsors which also plan to request orphan designation from the United States Food and Drug Administration (FDA), a common application form for use in both regions is now available on the EMA website.

EMA offers assistance to sponsors on the preparation of orphan designation applications through free pre-submission meetings. For more information contact: orphandrugs@ema.europa.eu.

Contrary to the US legislation on paediatric obligations (PREA), orphan-designated medicinal products are not exempted from the obligations of the paediatric regulation in the EU (see section 4.5). Sponsors are therefore encouraged to consider these requirements and discuss them during the pre-submission meeting.

---

105) ‘Sponsor’ means any legal or natural person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product.
Orphan marketing authorisation

Prior to the grant of a marketing authorisation, the COMP will review the criteria on which the orphan designation has been based to confirm the assumptions made at the time of designation. Accordingly, at the time of submission of the application for marketing authorisation, the applicant is asked to submit a report\(^\text{109}\) to EMA demonstrating that the orphan criteria are still met.

In accordance with article 8 of Regulation (EC) No 141/2000\(^\text{110}\), once a designated orphan medicinal product is authorised, it is granted a ten year period of market exclusivity. This market exclusivity protects the originator’s medicinal product in the authorised ‘orphan’ therapeutic indication. As such, ‘similar’ medicinal products will not be granted a marketing authorisation for the same therapeutic indication unless the originator gives consent, is unable to supply sufficient quantities of the medicinal product, or the second applicant demonstrates that, although similar, the medicinal product is clinically superior to the originator.

The definitions of ‘similar’ medicinal product and 'clinically superior', in this context, are laid down in article 3 of Commission Regulation (EC) No 847/2000\(^\text{111}\).

It is important for SMEs to note, when preparing an application for marketing authorisation, that, where a designated orphan medicinal product has been authorised for the condition which covers the proposed therapeutic indication being applied for, and a period of market exclusivity is in force, the possible ‘similarity’ with the authorised orphan medicinal product must be addressed in the application for marketing authorisation. If applicable, the applicant must then argue clinical superiority or justify that one of the derogations noted above applies.

The overall judgment of similarity includes an evaluation of the indication, the mechanism of action and the molecular structure.

4.5. Paediatric development

Requirements for the development and authorisation of medicines for use in children was introduced in the EU are set out in Regulation (EC) No 1901/2006\(^\text{112}\).

The overall aim is to improve the health of the children in the EU by increasing the research, development, and authorisation of medicines for use in children. To this end, a system of obligations, incentives and rewards has been put in place. It is imperative that SMEs familiarise themselves with these requirements very early on in development, to benefit from support offered and to avoid delays in the regulatory approval process.

System of obligations, incentives and rewards

The obligations and rewards listed below apply irrespective of the route of authorisation of the medicinal product (centralised vs. non-centralised).

For unauthorised medicinal products: There is an obligation to submit the results of studies conducted in compliance with an agreed paediatric investigation plan (PIP)\(^\text{113}\), to have an application for a new marketing authorisation being validated, and its assessment initiated. An exemption (waiver) from this obligation may be issued by EMA when such paediatric development is not needed or not appropriate. Deferrals may also be granted: this means that the initiation or completion of some or all the studies in the agreed PIP can occur after the company has applied for marketing authorisation in adults, in the same condition(s).

However, for deferred measures a binding date of initiation (where appropriate) and completion needs to be identified. It is therefore important to apply for the PIP (with or without deferral) or the waiver as early as possible.

Applications under certain types of legal bases (for example generic, biosimilar, homoeopathic and traditional herbal products, or those applied for as "well-established use") are exempt from these requirements.

For non-orphan medicinal products, the reward for conducting the paediatric development in compliance with a paediatric investigation plan is a six-month extension of the Supplementary Protection Certificate\(^\text{114}\), provided that the results of the studies are included in the product information and that authorisation is obtained in all EU Member States. This reward can be obtained even if the results of these studies fail to support a new paediatric indication.

For unauthorised orphan medicinal products: The obligations for unauthorised medicinal products outlined above also apply. The reward for orphan medicinal products is two years of market exclusivity in addition to the existing 10-year exclusivity awarded under the EU orphan regulation, if the results are included in the product information.


\(^{113}\) The PIP is a research and development programme, aimed at ensuring that the necessary data are generated to determine the conditions in which a medicinal product may be authorised for the paediatric population.

4. MEDICAL PRODUCTS DEVELOPMENT (HUMAN)

For authorised patented medicinal products: The requirements and rewards described above also apply when seeking a variation or extension of an existing marketing authorisation for a new indication (including paediatric), new route of administration or new pharmaceutical form, when the product is covered by a supplementary protection certificate or a qualifying patent. As with new medicines, waivers or deferrals may also be granted, and the rewards are the same as above. The PIP and/or waiver must cover all existing and new indications, pharmaceutical forms and routes of administration.

For "off-patent" medicinal products: Medicines not covered by a supplementary protection certificate or a qualifying patent, and developed solely for paediatric use and with an appropriate formulation can benefit from a specific type of marketing authorisation — the paediatric-use marketing authorisation (PUMA) — which grants 10 years of data protection. To apply for a PUMA, a PIP must be agreed with EMA beforehand, and will be subject to compliance check.

It is important for SMEs to be aware that there is a requirement to agree the paediatric investigation plan (PIP) early on, in the development of the medicinal product, i.e. not later than at the time human pharmacokinetic studies are completed in adults. The Agency, through its paediatric committee (PDCO) is responsible for assessing the content of paediatric investigation plans, waivers and deferrals and formulating an opinion, which is subsequently transformed into a decision.

The PIP covers the timing and measures required to study the safety and efficacy of the product, with an age appropriate formulation if relevant, in all paediatric subsets affected by the condition.

A revised guideline provides details on the format and content of applications for agreement or modification of a paediatric investigation plan, requests for waivers or deferrals, the operation of the compliance check and the criteria for assessing significant studies\(^\text{115}\). Further details on how to apply, including a questions & answers document\(^\text{116}\), are available on the Agency’s website\(^\text{117}\). There is no fee associated with these applications.

The Agency offers the possibility of a pre-submission meeting (via teleconference) for SMEs in advance of the submission of their application for a PIP and/or deferral and/or waiver. This is aimed at facilitating the validation of applications and is particularly recommended for (potential) orphan medicinal products. To discuss these meetings, contact paediatrics@ema.europa.eu.

The Agency also provides free Scientific Advice on the development of medicinal products for paediatric indications (see section 3.4).

Once the PDCO has agreed the PIP, the applicant company will need to comply with the plan, as the agreed PIP is binding for the company. As the development of the medicinal product progresses, there may be a need for companies to apply for a modification of the agreed PIP if it is no longer appropriate or unworkable. If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

A compliance check will be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, unless all measures in the PIP are deferred and there is no due date for initiation or completion of a study/measure. The same applies to some subsequent regulatory applications for authorised products, as described above. To prevent delays in the validation process, applicants are advised to submit compliance check requests to the PDCO at least 3 months in advance of submission of the regulatory application; multiple compliance check requests are also possible, for example after completion of separate studies/measures.

Other key measures in the paediatric regulation

These include:

- An increased transparency of paediatric information. The marketing authorisation holder should submit results of any paediatric studies (whether part of a PIP or not) to the concerned competent authority within 6 months of their completion. Protocols and results of paediatric clinical trials performed both inside the EU and anywhere else in the world, if the trial is part of a paediatric investigation plan, will be publicly available in the EU clinical trials register (EU CTR\(^\text{118}\), see section 4.3.6);

- EU funding for research on off-patent medicines for paediatric use may be delivered through the EU Horizon 2020 programme;

- Measures to increase the robustness of pharmacovigilance (safety monitoring) for medicines;

- An EU inventory of the therapeutic needs of children to focus research, development and authorisation of paediatric medicines;

\(^{116}\) http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000015.jsp&murl=menus/regulations/regulations.jsp&mid=WCOb01ac0580025b8e
\(^{118}\) https://www.clinicaltrialsregister.eu/
An Agency-based EU network of networks, investigators and trial centres with recognised expertise in performing clinical studies in children (EnprEMA119). Enpr-EMA acts as a contact point for a number of specialty and multi-specialty networks facilitating patient recruitment. It also offers expert advice when preparing a PIP application and provides access to academic partners through established collaboration with the SME office at EMA.

4.6. GMP/GDP/GCP/GLP

4.6.1. Good manufacturing practice (GMP)

Good manufacturing practice (GMP) is defined as that part of quality assurance which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use. The principles and guidelines for GMP are stated in two directives: Directive 2003/94/EC120 for medicinal products and investigational medicinal products for human use and Directive 91/412/EEC121 concerning veterinary medicinal products. Compliance with these principles and guidelines is mandatory within the European economic area. Interpretation of these requirements is provided in 'EU guidelines to good manufacturing practice - medicinal products for human and veterinary use'122 published by the European Commission. This guide to GMP consists of detailed guidelines (part I, II and III) which are supplemented by a series of annexes and related documents specific for certain types of product or topics.

A public site, EudraGMDP123, is also available to get information on manufacturing authorisations and GMP certificates.

The manufacture of medicinal products in the EEA is undertaken subject to the holding of a manufacturing and importation authorisation. Such authorisation is also required for imports from third countries into a Member State. The national competent authorities of Member States enter the manufacturing and importation authorisations that they issue into EudraGMDP.

Following a site inspection, a certificate of good manufacturing practice is issued to the manufacturer if the outcome of the inspection demonstrates that the manufacturer complies with the principles of GMP, as provided by EU legislation. The national competent authority which performs the inspection shall enter the GMP certificates information into EudraGMDP. If the outcome of the inspection is that the manufacturer does not comply with the principles of GMP, the information is also entered into EudraGMDP, as a GMP non-compliance statement.

Manufacturing authorisation holders are obliged to comply with GMP requirements for medicinal products and to use as starting materials only active substances manufactured in accordance with the guidelines on GMP for starting materials. The falsified medicines Directive 2011/62/EU124 introduced strengthened provisions for the supervision of active substance manufacture, which includes an obligation for national competent authorities to register active substance manufacturers, importers and distributors established on their territories. The active pharmaceutical ingredient (API) registration certificates are publicly accessible through the EudraGMDP database. Finished product manufacturers are required to verify that the active substances used in their products are manufactured according to GMP through audits of the manufacturer. The details of how the assessment of non-EEA countries will be carried will be established by the European Commission through implementing measures. Further information is available on the European Commission's website125.

The occurrence of shortages of medicines due to manufacturing and quality problems has increased over the past few years. To report potential shortages of medicines caused by GMP-non-compliance or quality problems, SMEs should e-mail qdefect@ema.europa.eu and clearly indicate if the problem identified is likely to lead to a shortage. For further information, a reflection paper (EMA/590745/2012)126 has been published on the EMA website.

123) http://eudragmdp.ema.europa.eu/inspections/displayWelcome.do?jsessionid=H7dOUpkrSw2x7vkJflIIHlgbBUKOMICZyvHPQ2T54DisOayPwCt-940175144
125) For more information on falsified medicines: http://ec.europa.eu/health/human-use/falsified_medicines/index_en.htm
4.  MEDICAL PRODUCTS DEVELOPMENT (HUMAN)

4.6.2. Good distribution practice (GDP)

The wholesale distribution of medicinal products is an important activity in the integrated supply chain management. Good distribution practice (GDP) should be implemented through a quality system operated by the distributor or wholesaler. The aim of GDP is to ensure that that the level of quality of authorised medicines, determined by GMP, is maintained throughout the distribution network to retail pharmacists and others entities selling medicines to the general public. The quality system should also ensure the right products are delivered to the right addressee within a satisfactory time period. A tracing system should enable any faulty products to be found and there should be an effective recall procedure. The principles of GDP are stated in Directive 92/25/EEC127 and guidance on good distribution practice of medicinal products for human use has been published in a Commission guideline 2015/C 95/01.128

In order to strengthen the supervision by regulatory agencies of the supply chain for medicinal products for human use, the falsified medicines Directive 2011/62/ EU129 introduced stricter obligations for wholesale distribution authorisations issued by Member States, GDP certificates and non-compliance reports.

4.6.3. Good clinical practice (GCP)

Good clinical practice (GCP) concerning human medicinal products is an international ethical and scientific quality standard for designing, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and wellbeing of trial subjects are protected; consistent with the principles that have their origin in the declaration of Helsinki, and that the clinical trial data are credible. Requirements for the conduct of clinical trials in Europe including GCP and GMP and inspections of these, have been implemented in the clinical trial directive (Directive 2001/20/EC)130 and GCP directive (Directive 2005/28/EC)131 published in the ‘Eudralex – volume 10 clinical trials guidelines’.132 Both directives will, in the future, be repealed by the new Clinical Trials Regulation (EC) No 536/2014. Clinical trials included in any marketing authorisation application in the EU are legally required to be conducted in accordance with GCP.

For clinical trials of veterinary products, the EU has adopted the Veterinary ICH GL9 ‘guideline on good clinical practices’ CVMP/VICH/595/98133, which provides guidance on the design and conduct of all clinical studies of veterinary products in the target species. It is directed at all individuals and organisations involved in the design, conduct, monitoring, recording, auditing, analysis and reporting of clinical studies in target species and is intended to ensure that such studies are conducted and documented in accordance with the principles of GCP. The annex to Directive 2001/82/EC134, as amended, sets out conditions for the conduct of clinical trials included in applications for marketing authorisation.

4.6.4. Good laboratory practice (GLP)

Good laboratory practice (GLP) defines a set of rules and criteria for a quality system concerned with the organisational process and the conditions under which non-clinical studies are planned, performed, monitored, recorded, reported and archived. Detailed information about GLP can be found on the linked websites of the organisation for economic co-operation and development (OECD)135 and the European Commission136 (see Directive 2004/9/EC137 and Directive 2004/10/EC138). For human products, annex I to Directive 2001/83/EC139, as amended, indicates that safety tests reported in marketing authorisation applications should be performed in compliance with the principles of GLP. For veterinary products, in accordance with annex I to Directive 2001/82/EC140, as amended, the same principles apply as well as for tests carried out for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

134) http://www.oecd.org/env/glp
4.6.5. Inspections

GMP, GLP, GCP and PhV inspections may be requested in connection with an application for a marketing authorisation at national or a EU level. The sites to be inspected (manufacturing and quality control sites, non-clinical study sites, clinical trials sites or sites where pharmacovigilance activities are conducted) should be “inspection ready” at the time of submission of the application and throughout the assessment.

EMA is responsible for the co-ordination of pre-authorisation GMP, GLP, GCP and pharmacovigilance inspections in connection with the granting of a marketing authorisation by the Union. All information concerning centralised inspections activities can be found on the inspection section of the external EMA web page.

In case of an accelerated assessment procedure (see section 6.14.1) the applicant is encouraged to contact EMA prior to submission of the request in order to determine the need for any pre-authorisation inspection. Further information is available in the pre-submission guidance.

141) http://eudragmdp.ema.europa.eu/inspections/displayWelcome
142) http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000021.jsp&murl=menus/regulations/regulations.jsp&mid=WCOb01ac0580022711&jssaved=true
5. MEDICINAL PRODUCT DEVELOPMENT (VETERINARY)
5. Medicinal product development (veterinary)

The data requirements for an application for marketing authorisation for a veterinary medicinal product are laid down in EU legislation, in particular annex I of Directive 2001/82/EC. Further guidance is available in the scientific guidelines adopted at VICH and EU level as well as in the notice to applicants in the scientific guidelines adopted at VICH and EU level as well as in the notice to applicants143. In addition, many veterinary products are subject to the requirements of individual European pharmacopoeia monographs. Foodstuffs obtained from animals treated with veterinary medicinal products must not contain residues which might constitute a health hazard to the consumer. Therefore, no marketing authorisation for any veterinary medicinal product intended for food-producing animals can be granted in the European Union unless maximum residue limits (MRLs) have been established for any pharmacologically active substance contained in the product. The establishment of MRLs is a Community procedure regulated by Regulation (EC) No 470/2009144. The requirement for MRLs applies to the active principle(s) but also excipients or adjuvant, if they are pharmacologically active.

An overview of the studies required to establish the safety and efficacy of a medicinal product for veterinary use as well as MRLs is provided in section 5.1. For detailed information, SME companies should consult volume 8 of the rules governing medicinal products in the European Union145 and the EMA website where all current scientific guidelines are published (see section 3.5).

To ensure that the appropriate studies are performed and that there are no major objections regarding the study design at the time of the evaluation of the marketing authorisation application, SMEs are particularly encouraged to seek scientific advice from EMA (see section 3.4).

5.1. Maximum residue limits (MRL)

In order to establish or modify MRLs for residues of veterinary medicinal products in foodstuffs of animal origin, an application should be submitted to the Agency for evaluation by the CVMP. Procedural and administrative information e.g. dossier contents are explained in volume 8146 of the rules governing medicinal products in the EU and EMA procedural guidance147.

Safety and residue studies have to be conducted and submitted with an MRL application. These studies are intended to demonstrate that no harmful residues result in foodstuffs of animal origin from the normal conditions of use of the substance under consideration. Details on the studies to be conducted can be found on the EMA website148.

Safety studies should include pharmacological, toxicological and other relevant studies such as studies on potential microbiological activity. The toxicological studies include repeat-dose toxicity, reproduction and developmental toxicity, genotoxicity and carcinogenicity testing, and testing of other effects, e.g. delayed neurotoxicity, where appropriate due to the type of substance.

The safety studies are required to establish the acceptable daily intake (ADI). The ADI is an estimate of the substance and/or its residues, expressed in terms of µg or mg per kg body weight that can be ingested daily over a lifetime without any appreciable health risk to exposed individuals.

Residue studies, including pharmacokinetics tests, are required to determine the nature and actual level of residues and their elimination in the target animal and in particular edible tissues (muscle, fat or fat and skin, liver and kidney) and other food products of animal origin (milk, eggs or honey). Therefore, investigations of the elimination of residues from edible tissues and other food products of animal origin should be conducted. In order to allow the validation of the residue depletion studies and for the purpose of residue control, validated analytical methods for identifying and measuring the residues in the tissues and food products should be developed.

On the basis of the safety and residue studies, MRLs are established for the animal species for which the veterinary medicinal product is intended to be used (e.g. cattle). Where extension of existing MRLs to other animal species (e.g. extension to pigs) or specific food commodities (e.g. milk, eggs) is considered, only residue studies with regards to the relevant target species should be performed, because the ADI is the same regardless of the indications.

147) http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000039.jsp&mid=WCOb01ac0580064889
Modifications of the MRLs can be requested, if new safety studies allow the modification of the ADI, or if new residue studies allow amendment of the MRLs.

At the end of the evaluation process the CVMP adopts an opinion, which is then submitted to the European Commission for adoption by the standing committee. Depending on the conclusions a pharmacologically-active substance may be included in table 1 (allowed substances) or table 2 (forbidden substances) of Commission Regulation (EU) No 37/2010149. Table 1 (allowed substances) of the regulation includes substances for which MRLs, including provisional MRLs, have been established, and substances for which it was concluded that consumer safety could be ensured without the need to establish MRL values. Table 2 (forbidden substances) includes substances for which no safe limit could be established or for which there were insufficient data to allow a recommendation for inclusion of the substance in table 1. Specific questions on MRLs can be addressed to: MRL@ema.europa.eu.

5.2. Quality

A common quality section, covering both medicinal products for human use and veterinary use, has been provided in this guide for ease of reference (see section 4.1).

5.3. Safety

The safety of a product has to be demonstrated through “safety” studies, and for products intended for food-producing species also with “residue” studies. This part of development should address safety for the target animal (companion animals or food producing species), consumer safety, user safety and the environmental impact of the product.

Safety studies investigate the active substance(s) and excipients, if relevant. The research should focus both on the pharmacology (pharmacodynamics and pharmacokinetics) and toxicology.

The pharmacodynamic studies should take into account tests in experimental and target animals. The pharmacokinetic studies should investigate the absorption of active substance, its distribution, metabolism and excretion in animals.

Toxicology studies should assess single and repeated dose toxicity, tolerance in the target species, reproduction and developmental toxicity, genotoxicity and carcinogenicity. Tests on other effects such as immunotoxicity, dermal or eye irritation, neurotoxicity and antimicrobial properties might also be needed depending on the veterinary medicinal product. For products for food-producing animals many of the safety studies required for marketing authorisation will have been provided in the preceding MRL application.

An assessment of the user safety should be conducted, evaluating the risks for the persons that may be exposed to the product (e.g. pet owners, veterinarians, farmers) based on the safety studies conducted and considering the potential exposure.

An environmental risk assessment is required for all applications. The environmental risk assessment is conducted in two phases. In phase I an exposure driven screening is conducted to determine if the product leads to an extensive exposure of the environment. In most cases only data already available in the dossier are required. If, based on the conclusions of the phase I assessment, an in depth environmental risk assessment become necessary, specific investigations on the effects and fate in environment e.g. studies on effects on aquatic organisms and biodegradation, will be required (phase II assessment).

Residue studies to establish a withdrawal periods should be carried out if the product is intended for use in food producing animals. These studies should include research on pharmacokinetics in the target species following administration by the intended route and take into account the edible tissues muscle, fat or fat and skin, liver and kidney, as well as milk, eggs or honey, as appropriate.

5.4. Efficacy

The efficacy of a product can be demonstrated with “pre-clinical” and “clinical” studies.

Preclinical studies should investigate the pharmacology, dose selection, tolerance in the target animal species and resistance development, if relevant. Usually these studies are undertaken in healthy animals, although some studies may also involve diseased animals.

Pharmacology studies should investigate the pharmacodynamics and pharmacokinetics (absorption, distribution, metabolism, excretion) relevant for the application i.e. for the proposed indication, dosage, route of administration and target species.

The pre-clinical studies should address the dose selection; this is usually done with dose determination (titration) studies. In the absence of such studies, e.g. for certain product classes or indications where such studies cannot be performed or would not provide adequate data, a justification for the proposed dose should be provided including references to other appropriate studies (e.g. dose confirmation/field studies).

5. MEDICINAL PRODUCT DEVELOPMENT (VETERINARY)

Tolerance in the target species should usually be demonstrated by target animal tolerance studies using multiples of the recommended daily dose over an extended time period. In addition and/or in cases where such studies cannot be conducted (e.g. for ethical reasons), this should be justified and other appropriate studies such as field or dose determination studies should be provided.

For antibiotic or anthelmintic products, the possibility of resistance development should be investigated in view of the potential impact on the efficacy of the product.

**Clinical studies** are performed in diseased animals, under laboratory and, ideally, under field conditions. These studies should provide a clear picture of the therapeutic efficacy and safety of the product, in comparison with other product(s) authorised for the same indication (positive control) or untreated animals (negative control). Field trials should include sufficient animal numbers and should usually be conducted in Europe with the final product formulation using the proposed dose, route and duration of administration. They should take into account different climatic/animal husbandry systems, especially for products such as anti-infectives and anthelmintics.

5.5. Immunologicals

Due to the widespread use of bovine serum in many veterinary medicinal products (IVMPs), specific measures concerning the prevention of the transmission of animal spongiform encephalopathies may be required (see section 4.1.3).

The testing for extraneous agents is particularly relevant for IVMPs and due note should be taken of the relevant guidelines concerning this issue. Annex I to Directive 2001/82/EC and the Ph. Eur. monographs on vaccines and immunosera for veterinary use (0062 0030) requires the testing of immunological veterinary medicinal products for potential contaminants. Further guidance is available on the EMA website150.

If the IVMP contains or consists of genetically modified organisms (GMOs), as defined by Directive 2001/18/EC, the requirements of article 31 (2) of Regulation EC No 726/2004 on the authorisation of veterinary medicinal products which contain or consist of GMOs should be fulfilled.

Various tests and/or field studies should be conducted to show the potential risks from the product under the proposed conditions of use including target animal safety. For live vaccines, the assessment should focus on the potential shedding by vaccinated animals, the risk to unvaccinated animals or any other species and the potential of the strain used to revert to virulence.

Various tests and/or field trials should be conducted to confirm efficacy of the product in relation to all claims made for the product with regards to the properties, effects and use.

5.6. GMP/GDP/GLP/GCP

A common GMP/GDP/GLP/GCP section, covering both medicinal products for human use and veterinary use, is provided in this guide for ease of reference (see section 4.6).

5.7. MUMS/limited market products

The data requirements for products classified as intended for MUMS/limited market by CVMP may be more flexible and are decided on a case by case basis in accordance with the published CVMP MUMS guidelines151 on quality, safety, efficacy, and immunologicals. Products are authorised in accordance with Directive 2001/82/EC as amended, but data requirements can be discussed with the regulatory authorities in advance of any submission or by requesting scientific advice on the dossier requirements. The MUMS/limited market policy and supporting guidance is published on the Agency website along with information on how to request a classification by CVMP. Specific questions may be sent to VetMUMSapplications@ema.europa.eu.

---


151) [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000173.jsp&mid=WC0b01ac058002d89a]
6. APPLICATION FOR CENTRALISED MARKETING AUTHORISATION
6. Application for centralised marketing authorisation

6.1. Access to the centralised procedure

The centralised procedure is mandatory for certain types of human medicinal products such as those developed by certain biotechnological processes, advanced therapy medicinal products, designated orphans, and those containing new active substances for the treatment of acquired immune deficiency syndrome, cancer, neurodegenerative disorders, diabetes, auto-immune diseases, other immune dysfunctions and viral diseases.

The centralised procedure may also be used on a voluntary basis for other medicinal products containing a new active substance, or medicinal products which constitute a significant therapeutic, scientific or technical innovation or that the granting of an EU marketing authorisation would be in the interests of patients at EU level. It is also an option for certain medicinal products intended for paediatric use, or for generics of reference medicinal products authorised through the centralised procedure. Further guidance on the mandatory (EMA/CHMP/121944/2007) and optional scope of the procedure. Further guidance on the mandatory (EMA/CHMP/121944/2007) and optional scope of the centralised procedure is given in the pre-submission questions & answers on the EMA website.

The centralised procedure is mandatory for veterinary products developed by certain biotechnological processes and for medicinal products intended primarily for use as performance enhancers. The centralised procedure may be used on a voluntary basis for products containing a new active substance, other innovative products, veterinary products for which the granting of an EU marketing authorisation would be in the interests of animal health at EU level, and immunological products for the treatment of animal diseases subject to EU prophylactic measures.

Regardless of whether the product falls into the mandatory or optional scope, an ‘eligibility request’ should always be submitted using the ‘pre-submission request form’ template together with relevant additional justification in annex (e.g. draft SmPC, and for optional scope a justification for eligibility). The applicant should address the documents by email to CPEligibility@ema.europa.eu or vet.applications@ema.europa.eu respectively.

EMA recommends applicants to submit an eligibility request, preferably, at the earliest 18 months before submission of the marketing authorisation application (MAA), and at the latest 7 months before the MAA is filed with EMA, at which point it may be submitted together with the “letter of intent to submit”.

For veterinary applications, an eligibility request for the centralised procedure may be checked at any time. However a letter of intent (i.e. official notification that an applicant will submit an eligible application) should be made at least 7 months in advance of any submission date.

Following discussion at CHMP or CVMP, EMA will inform the applicant of the outcome of the eligibility procedure. Further guidance on how to request access to the centralised procedure, is given in the EMA presubmission guidance (human and veterinary).

6.2. Selection of rapporteur/co-rapporteur

For any scientific evaluation in the centralised procedure a ‘rapporteur’, and if relevant a ‘co-rapporteur’, will be appointed from the members of the CHMP/CVMP or the alternates. A (co-)rapporteur from the pharmacovigilance risk assessment committee (PRAC) will also be appointed for all new medicinal products for human use and for advanced therapy medicinal products, a (co-)rapporteur will also be appointed by the committee for advanced therapies (CAT). The role of the (co-)rapporteur is to perform the scientific evaluation and to prepare an assessment report for the relevant committee according to an agreed timetable.

The appointment of the rapporteur/co-rapporteur is made on the basis of objective criteria, which will ensure the provision of objective scientific opinions and will allow the use of the best and available expertise in the EEA in the relevant scientific area.

The appointment process for rapporteur/co-rapporteur is usually initiated at the CHMP/CVMP meeting following the receipt of the ‘pre-submission request form’ (intent to submit MA) and their request to assign rapporteurs, which should optimally be provided seven months before the intended MAA submission date. Such appointment can be, but is not always, connected to a possible earlier request for eligibility for assessment via the centralised procedure (see section 6.1). For human use products which are eligible to the PRIME scheme, rapporteur appointment takes place earlier (see section 3.2). Further guidance on the appointment of rapporteur and co-rapporteur for human

medicinal products (EMA/151751/2010)\textsuperscript{157} and veterinary medicinal products (EMA/CVMP/468877/2009)\textsuperscript{158}, is given on the EMA website.

If the intended application is deemed to be admissible, EMA will inform the applicant of the names of the (co-)rapporteur(s) appointed and will provide information on the dossier requirements of the committee members.

The rapporteur and co-rapporteur will select the experts of their assessment teams from the list of European experts\textsuperscript{159} accessible through the EMA website.

6.3. (Invented) Name of products evaluated via the centralised procedure

The centralised procedure requires one single name for the medicinal product to be authorised that may be either an invented name not liable to confusion with the common name, or a common name or scientific name accompanied by a trademark or the name of the Marketing Authorisation Holder. A common name is the international non-proprietary name (INN) recommended by the World Health Organisation, or, if one does not exist, the usual common name.

Although it is not mandatory under EU legislation, many companies submitting marketing authorisation applications under the centralised procedure use invented names for their medicinal products. EMA assesses whether the invented name proposed for a medicinal product could create a public-health concern or potential safety risks. For human medicinal products, details about the criteria used for checking the proposed invented names are detailed in the guideline on the acceptability of names for human medicinal products processed through the centralised procedure\textsuperscript{160}. For veterinary medicinal products there is a separate guideline on the acceptability of names for veterinary medicinal products processed through the centralised procedure (EMA/248010/2007)\textsuperscript{161}.

Further information on how to submit (invented) name(s) for review, including the request form for completion and submission timelines, can be found in the pre-submission guidance on the EMA website for both human\textsuperscript{162} and veterinary medicinal products\textsuperscript{163}.

6.4. EMA contact point in the centralised procedure

For initial marketing authorisation application (MAA) for human medicines, a Procedure Manager (PM) is allocated at time of confirmation of eligibility to the centralised procedure and is the primary contact point for the applicant prior to submission and throughout the procedure until the decision is granted by the European Commission.

The PM will serve as the main liaison person between the EMA product team, the Rapporteurs and the applicant. The PM, in close co-operation with the EMA Product Lead (EPL) and the rapporteurs, will ensure that the applicant is kept informed of all aspects related to the MAA evaluation.

The applicant should contact the PM for all procedural questions regarding the application, during the pre-submission and evaluation phases.

Questions concerning the validation of the MAA, once submitted, will be dealt with by an assigned Validation Officer.

At certain milestones during the evaluation procedure, the EPL will contact the applicant to facilitate the discussion on the scientific evaluation of the dossier. These include clarification and Oral Explanation meetings, feedback from committee discussions, discussion on post-authorisation measures and product information. These interactions occur in close co-operation with the Rapporteurs.

Occasionally other members from the EMA Product team may contact the applicant directly to facilitate the discussion on specific aspects (e.g. quality, risk management, mock-up review).

Further information on the EMA contact point during a marketing authorisation application evaluation procedure can be found in the pre-submission guidance available on the EMA website\textsuperscript{164}.

For veterinary products a project manager is appointed for each application.
6. APPLICATION FOR CENTRALISED MARKETING AUTHORISATION

Figure 2 - Overview of the centralised procedure

- 7 MONTHS
  EMA notifies rapporteur/co-rapporteur

2 WEEKS
  Application - Validation

210 DAYS
  CxMP scientific assessment
  CxMP opinion

120 DAYS
  Applicant not in agreement with the opinion may request a re-examination
  Final opinion

67 DAYS
  CxMP opinion
  European Commission
  Draft Commission decision
  Standing committee
  Decision granting EU marketing authorisation
6.5. EMA pre-submission meeting

When preparing the submission of a marketing authorisation application, applicants have the opportunity to meet EMA to discuss procedural or regulatory issues in relation to the upcoming submission, and to establish contacts with EMA staff that will be involved with the application. Experience has shown the usefulness of these “pre-submission meetings”, even where the applicant has experience with the centralised procedure. Applicants are therefore strongly advised to request such a meeting. Guidance on pre-submission meetings with EMA can be found in the EMA pre-submission guidance for human and veterinary products on the EMA website.

Pre-submission meetings are free of charge and should take place approximately 6-7 months prior to the anticipated date of submission of the application. A completed pre-submission meeting request form for human or veterinary medicines detailing the topics for discussion should be sent to EMA: to pa-bus@ema.europa.eu for human products and to vet.applications@ema.europa.eu for veterinary applications.

6.6. Compilation of the application dossier

Data generated from pharmaceutical tests, non-clinical and clinical tests and trials with the medicinal product concerned, as well as other information required by the EU legislation, need to be provided to EMA and all CHMP/CVMP members for evaluation.

The application dossier for medicinal products for human use must be presented in accordance with the EU-CTD (common technical document) presentation outlined in volume 2B of the notice to applicants published on the Commission website. The CTD is an internationally agreed format for the preparation of a well-structured application to be submitted to regulatory authorities in the three ICH (International Council for Harmonisation) regions of Europe, USA and Japan. The CTD gives no information on the content of a dossier, but provides for a harmonised format of presentation of the necessary data to support the application in accordance with the legal/scientific requirements of each region. The EU-CTD is organised in five modules: module 1 contains the specific EU administrative and prescribing information. The structure of modules 2, 3, 4, and 5 is common for all regions and will contain the high level summaries and quality, non-clinical and clinical documentation respectively. All applications need to be in English.

For veterinary medicinal products the application dossier should be presented in accordance with volume 6B of the notice to applicants published on the Commission website.

For medicinal products for human use, EMA has implemented electronic-only submission of applications for marketing authorisation with electronic Common Technical Document (e-CTD) as the required format. Since the 1st January 2010, eCTD has been the only acceptable electronic format for all applications and all submission types. Non-eCTD electronic applications are no longer a valid format for submission. The latest version of the ICH M2 eCTD specification can be found on the ICH website, and the current version of the eCTD EU module 1 specification can be found on the eSubmission website. Further guidance on eCTD submissions is also available in the harmonised guidance for eCTD submissions in the EU.

The use of the eSubmission Gateway or Web client is mandatory for all electronic Common Technical Document (eCTD) submissions through the centralised procedure. EMA does not accept submissions on CD or DVD for any applications for human medicines. More information is available on the eSubmission Gateway page.

For medicinal products for veterinary use, electronic only submissions are now accepted. Guidelines on eSubmissions for veterinary products are available on the Veterinary eSubmission page.

Detailed information on the submission requirements for EMA, (co-)rapporteur, and CHMP/CVMP members are given in the EMA pre-submission guidance on the EMA website. All eCTD format submissions for Centrally Authorised Products sent to EMA on eSubmission Gateway/Web Client are available via the Common Repository and are considered delivered to all National Competent Authorities’ representatives, alternates.
6. APPLICATION FOR CENTRALISED MARKETING AUTHORISATION

and scientific experts. Submission of additional copies directly to the NCAs on CD/DVD or via the Common European Submission Portal (CESP) is not needed as it might lead to validation issues and cause delays.

Submission requirements for procedures such as referrals, ASMFs, NAP submissions related to EMA coordinated procedures and ancillary medicinal substances in medical device are available on the EMA webpage178.

Since 1 January 2016, the use of the Electronic Application Form (eAF) is mandatory for all procedures in the EU (Centralised procedure, MRP, DCP and by default National procedure), for human and veterinary products. The electronic application forms should be used for all initial MAA, variations and renewal applications. The forms and all related guidance documents are available on the eAF website119.

The eAFs should always be submitted as a part of the submission dossier within the eCTD sequence or within the VNeeS folder structure.

For the product information (SmPC, labelling and package leaflet texts), EMA provides the applicant with a template of what must be included in these documents. The latest version of these templates for human180 and veterinary181 medicines are available on the EMA website182.

6.7. Submission and validation of the application dossier

Target dates for submission for human183 and veterinary medicinal products184 are published on the EMA website. If the original indicated submission date cannot be met, the applicant should immediately inform EMA, rapporteur and co-rapporteur. A delayed submission can have consequences for already planned activities of the assessment teams of the rapporteurs and co-rapporteurs.

EMA will check if the application meets all relevant legal and procedural EU requirements (‘validation’), before the start of the scientific evaluation. Applicants should be aware that for medicinal products for human use, a compliance check for paediatric requirements may be necessary (see section 4.5).

EMA will issue an invoice on the date of the notification of the administrative validation to the applicant, and fees will normally be payable within 45 days of the date of the said notification. For SME applicants, the fee payment may be deferred (see section 2.4).

6.8. Evaluation of the application

Once the application is validated, EMA starts the evaluation procedure at the monthly starting date published on the EMA website. EMA will ensure that the evaluation is finalised within 210 days (less any clock-stops for the applicant to provide a response to questions from the CHMP/CVMP).

The procedure can be summarised as follows:

In the first evaluation phase, the rapporteur and co-rapporteur prepare assessment reports on the application within 80 days (85 days for veterinary products). The assessment reports are sent to all other CHMP/CVMP members for comment and to the applicant for information. Following discussion of the assessment reports, the CHMP/CVMP adopts a “list of questions”, identifying ‘major objections’ and/or ‘other concerns’, which will be sent to the applicant by day 120. The CHMP/CVMP may consult scientific advisory groups (SAGs) in connection with the evaluation of specific types of medicinal products or treatments, to which the committee may ask for expert’s views on a number of points. Scientific advisory groups are established by the relevant committee. They consist of European experts selected according to the particular expertise required on the basis of nominations from the CHMP/CVMP or EMA.

The rapporteur and co-rapporteur then assess the applicant’s responses (second evaluation phase), submit their joint assessment for discussion to the CHMP/CVMP and, taking into account the conclusions of this debate, prepare a final assessment report which also includes the draft SmPC, labelling and package leaflet. The CHMP/CVMP will adopt such report together with a list of outstanding issues if necessary. Based on the content of the list of outstanding issues, an oral explanation with the applicant might be planned. Once the evaluation is completed within the 210 days, the CHMP/CVMP adopts a positive or negative opinion on whether to grant the authorisation.

---

182) http://www.ema.europa.eu Human regulatory / Product information / Templates or Veterinary regulatory / Product information / Templates
A more detailed standard timetable for the evaluation of an application in the centralised procedure is provided below:

<table>
<thead>
<tr>
<th>DAY</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Start of the procedure</td>
</tr>
<tr>
<td>80</td>
<td>Receipt of the assessment report(s) from rapporteur and co-rapporteur(s) by CHMP/CVMP members and EMA. Sent to applicant for information only.</td>
</tr>
<tr>
<td>100</td>
<td>Rapporteur, co-rapporteur, other CHMP/CVMP members and EMA receive comments from members of the CHMP/CVMP.</td>
</tr>
<tr>
<td>115</td>
<td>Receipt of draft list of questions (including the CHMP/CVMP recommendation and scientific discussion) from rapporteur and co-rapporteur.</td>
</tr>
<tr>
<td>120</td>
<td>CHMP/CVMP adopts the list of questions as well as the overall conclusions and review of the scientific data to be sent to the applicant by EMA. Clock stop.</td>
</tr>
</tbody>
</table>

The applicant is expected to respond within the timeframe agreed by the CHMP/CVMP from the date of receipt of the questions, which is usually 3 months for human medicinal products. Applicants may request an additional 3-month period by writing to the CHMP chairman outlining their reasons. For veterinary procedures, the standard timeframe for response is 6 months, which may be extended upon justified request. If the applicant is unable to respond within the timeframe, then careful consideration should be given to withdrawing the application and resubmitting, if necessary after obtaining scientific advice, when the full information is available.

Further guidance on the response time for procedures relating to human medicinal products is provided in the EMA guidance (EMA/75401/2006) on the EMA website.

<table>
<thead>
<tr>
<th>DAY</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>121</td>
<td>Submission of the applicant’s responses, including revised SmPC, labelling and package leaflet texts in English. Restart of the clock.</td>
</tr>
</tbody>
</table>

After receipt of the responses, the following standard timetable applies:

<table>
<thead>
<tr>
<th>DAY</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>150</td>
<td>Joint response assessment report from rapporteur and co-rapporteur received by CHMP/CVMP members and EMA. Sent to applicant for information only.</td>
</tr>
<tr>
<td>170</td>
<td>Deadline for comments from CHMP/CVMP members to be sent to rapporteur and co-rapporteur, EMA and other CHMP/CVMP members.</td>
</tr>
<tr>
<td>180</td>
<td>CHMP/CVMP discussion and decision on the need to adopt a list of “outstanding issues” and/or an oral explanation by the applicant. If an oral explanation is needed, the clock is stopped to allow the applicant to prepare the oral explanation. Clock-stop.</td>
</tr>
</tbody>
</table>

Applicants should normally respond (or prepare for an oral explanation) within one month. In exceptional circumstances, an extension may be granted if scientifically justified.

<table>
<thead>
<tr>
<th>DAY</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>181</td>
<td>Restart of the clock and oral explanation (if needed).</td>
</tr>
</tbody>
</table>

Information on how oral explanations are conducted (EMA/748003/2014) is available on the EMA website.

At the conclusion of the oral explanation, representatives of the applicant will be invited to leave and the CHMP/CVMP will discuss and provide a preliminary recommendation on the acceptability of the application. The applicant will be informed of the trend at CHMP/CVMP level at the end of the scientific discussion ahead of any formal vote to conclude the evaluation process.

<table>
<thead>
<tr>
<th>DAY</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>By 210</td>
<td>Adoption of CHMP/CVMP opinion + CHMP/CVMP assessment report (and timetable for the provision of product information translations)</td>
</tr>
</tbody>
</table>

EMA will prepare a “summary of opinion” (for positive as well as negative opinions) in liaison with the applicant. Such summaries will be published on the EMA website after the adoption of the CHMP/CVMP opinion.

---

6. APPLICATION FOR CENTRALISED MARKETING AUTHORISATION

If an applicant decides to withdraw its application before an opinion is adopted, EMA will make this public on its website together with the relevant assessment report.

**Evaluation of the risk management plan by the PRAC for human medicines**

Applicants are required to submit a risk management plan at the time of marketing application and keep it updated during the lifecycle of the product. The RMP will be subject to review by the pharmacovigilance risk assessment committee (PRAC) in parallel to the CHMP review.

For more information on the RMP, please refer to GVP module V\(^1\)\(^88\) and the EMA website\(^1\)\(^89\) (see also section 7.1).

**Evaluation of advanced therapy medicinal products by the CAT**

For advanced therapy medicinal products (ATMPs) the scientific evaluation is carried out primarily by the committee for advanced therapies (CAT), which prepares the draft opinion on the quality, safety and efficacy for final approval by the CHMP. For this reason, a slightly different timetable applies to ATMP applications.

For more information on the ATMPs evaluation procedure, please refer to the following guidance: EMA/CHMP/50745/2005\(^1\)\(^93\).

**6.9. Re-examination of the CHMP/CVMP opinion**

The applicant may notify EMA/CHMP/CVMP in writing of their intent to request a re-examination of the CHMP/CVMP opinion within 15 days of its receipt (after which if such a request is not made, the opinion becomes final). Upon receipt of the notification of intent, the CHMP/CVMP will appoint a new set of (co)rapporteur to re-examine its opinion. The detailed grounds for the re-examination request must be forwarded to EMA within 60 days after receipt of the opinion. The applicant may also request review by the relevant scientific advisory group (SAG).

At the end of the re-examination procedure, the CHMP/CVMP will adopt a final opinion either confirming its previous opinion or changing that opinion on the application. If considered necessary, an explanation can be held within this 60 days’ timeframe, as well as consultation of a SAG. No clock-stops apply to this procedure.

For further guidance on the re-examination procedure for human medicinal products and CHMP timetable for assessment (EMA/CHMP/50745/2005 Rev 1)\(^1\)\(^91\), please refer to the EMA website. For veterinary medicinal products, please refer to the veterinary procedural advice (EMA/CVMP/2128/2007-Rev1)\(^1\)\(^92\).

For ATMPs, please refer to the following guidance: EMA/CHMP/50745/2005\(^1\)\(^93\).

**6.10. Conditions to the marketing authorisation**

The marketing authorisation holder (MAH) can be imposed the obligation to conduct post-authorisation measures. These conditions, whilst not precluding the approval of a marketing authorisation or other post-authorisation procedures, are considered to be key to the benefit-risk balance of the product.

These obligations can be imposed at the time of the granting of the marketing authorisation or later. These can consist of post-authorisation safety or efficacy study, or additional pharmacovigilance activity included in the Risk Management Plan (see also 7.2).

**6.11. Post-authorisation efficacy studies (PAES)**

To support a benefit-risk for a medicine, demonstration of benefit is required from trials that are appropriately designed and conducted in accordance with applicable guidance. A PAES may nevertheless be needed to increase the understanding of therapeutic efficacy. This is in keeping with the concept of life-cycle product benefit-risk profiling through targeted post-authorisation research.

Delegated Regulation (EU) No 357/2014\(^1\)\(^94\) provides details on PAES that may be imposed at time of, or after the marketing authorisation of centrally (CAPs) and nationally authorised medicinal products (NAPs). Guidance\(^1\)\(^95\) on PAES within or outside the scope of Delegated Regulation (EU) No 357/2014 is currently being developed (see also 7.2).
6.12. Publication of clinical data for medicinal products for human use (‘policy 0070’)  

EMA proactively publishes the clinical reports submitted under the centralised procedure for human medicines after consultation with the company on the redaction of commercially confidential information (CCI) and the anonymisation of protected personal data (PPD). The policy applies to clinical reports contained in all initial MAAs submitted on or after 1 January 2015, and to applications submitted on or after 1 July 2015 for extension of indication or line extension, irrespective of the dossier outcome.

The data published are module 2.5 (clinical overview), module 2.7 (clinical summary), module 5 [clinical study reports (CSRs) and appendices 16.1.1 (protocol and protocol amendments), 16.1.2 (sample case report form) and 16.1.9 (documentation of statistical methods)]. Such data either use the common technical document (CTD) format or another format.

The publication process includes the submission of a “redaction proposal version”, a consultation phase and the submission of a “final redacted version”.

The timeline for providing a “redaction proposal version” package by the company depends on the procedure (i.e. initial MAA, line extension applications, extension of indication applications, withdrawn applications) and is determined at CHMP opinion stage.

The proposed CCI redactions, the anonymisation report outlining compliance in the treatment of the PPD, including a review of PPD redactions/anonymization is assessed by EMA in a “redaction proposal version” package. EMA communicates its conclusion and comments for the entire set of the submitted clinical reports after consulting the company.

The company then carries out the redactions using its redaction tool to create a “final redacted version” of each clinical report. The final package is sent as a new eCTD sequence to EMA for publication.

Redacted/anonymised clinical reports are published by EMA on its corporate website. Prior to publication, EMA will watermark each page of the clinical reports in the “final redacted version”. For MAAs, line extension applications and extension of indication applications, the redacted/anonymised clinical reports will be published within 60 days of the issuance of the EC decision. For withdrawn applications, the publication of the redacted/anonymised clinical reports will take place within 150 days after the receipt of the withdrawal letter.

Software licence for a redaction tool to SMEs  

The choice of the redaction tool is a decision to be taken by each MAH. A license for a redaction tool is available to SMEs free of charge.

SMEs are advised to write to EMA five months prior to the CHMP opinion to apply for the redaction tool licence. The SME status needs to be valid at the time of the application to qualify for the redaction tool licence.

For more details on policy 0070, including procedural aspects, identification and redaction of CCI, anonymisation of PPD, application for software licence for a redaction tool, SMEs are advised to refer to the guidance on the EMA website.

6.13. Decision-making process  

After adoption of the CHMP/CVMP opinion, EMA has 15 days to forward its (final) opinion to the Commission. This is the start of the “decision-making process”, whereby the CHMP/CVMP Opinion will be turned into a legally binding Commission decision for all Member States and the applicant.

The Commission decision granting a marketing authorisation to the medicinal product concerned includes the agreed SmPC, conditions for use, labelling and package leaflet texts (product information). The Commission decision is legally binding on all Member States, the product information must, therefore, be provided in all EU languages. The translations of the product information are normally provided by the applicant five days after adoption of the CHMP/CVMP opinion.

Further details on the handling of translations (EMA/5542/02) are available on the EMA website. For SME applicants, EMA will provide translations of product information (summary of product characteristics, label and package leaflet and relevant annexes) into the EU official languages. The translations will be reviewed by the Member States before transmission to the Commission (see section 2.4.1).

During the decision-making process, the Commission services check that the marketing authorisation complies with Union law, consulting various Commission directorates-general. In addition, the Commission consults the standing committee, which consists of representatives of all EU Member States. The opinion of the standing committee will normally be given by written procedure.

196) http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000555.jsp&mid=WC0b01ac0580999a9d
The Commission prepares a draft Commission decision within 15 days. Member States have 22 days to forward their written observations on the draft decision to the Commission. Within this time-limit, Member States must inform the Commission whether they approve the draft, reject it, or abstain. Any Member State failing to respond within the time-limit to express its opposition or intention to abstain from voting is deemed to have approved the draft.

The Commission will take a final decision within 15 calendar days after the end of the standing committee phase. The decision will be sent to the applicant and published in the EU “Official Journal”.

The EU marketing authorisation for the medicinal product will be granted in 67 days after adoption of the final CHMP/CVMP opinion.

Once the EU marketing authorisation is granted, EMA will publish the CHMP/CVMP assessment report on the medicinal product which includes the reasons for its opinion in favour of granting authorisation, after deletion of any information of commercially confidential nature. This document is called the European public assessment report (EPAR). The EPAR includes a summary, in all EU languages, written in a manner that is understandable to the public. EPARs and their summaries are published on the EMA website.

A marketing authorisation for a medicinal product is generally valid for five years. There is an exception when a conditional marketing authorisation for human medicinal products has been granted (see sections 6.10. and 6.14.2). The marketing authorisation may be renewed after five years on the basis of a re-evaluation by EMA/CHMP/CVMP of the benefit-risk balance of the product, upon application by the holder at least six months before expiry. Once renewed, the marketing authorisation shall be valid for an unlimited period, unless the Commission decides on the basis of the CHMP/CVMP recommendation that, due to justified grounds relating usually to pharmacovigilance, there is a need to proceed with one additional five-year renewal.

6.14. Early access to the EU market

An overview of the support available for early access is available on the EMA website.


In order to meet the expectations of patients as well as animal owners and to take account of the increasingly rapid progress of science and therapies, it is possible to obtain a marketing authorisation via an ‘accelerated assessment procedure’ (that is, within up to 150 days instead of 210 days) for products which are of major public or animal health interest particularly those bringing a therapeutic innovation.

Any request for accelerated assessment should be made as early as possible before the actual submission of the marketing authorisation application. The request should elaborate on the major benefits expected and present the arguments to support the claim that the medicinal product introduces new methods of therapy or improves on existing methods, thereby addressing to a significant extent the greater unmet needs for maintaining and improving public health.

Medicinal products for human use eligible to the PRIME scheme can receive an early confirmation of their eligibility to an accelerated assessment at the time of marketing authorisation application (see 3.2).

For further details refer to the EMA pre-submission guidance for human medicinal products and the EMA pre-submission guidance for veterinary medicinal products. Additionally, please refer to corresponding CHMP and CVMP guidelines (EMA/CHMP/671361/2015 Rev. 1 and EMA/32995/06, respectively).

6.14.2. Conditional marketing authorisation (human medicines only)

In addition to accelerated assessment (cf. 6.14.1), in order to meet unmet medical needs of patients and in the interests of public health, the CHMP can recommend the granting of marketing authorisations on the basis of less complete data than is normally required. In such cases, the granting of a marketing authorisation is subject to certain specific obligations and has to be renewed annually (‘conditional marketing authorisation’).

This may apply to medicinal products used in seriously debilitating or life-threatening diseases, emergency situations in response to public health threats, or products designated as orphan medicinal products.

199) www.ema.europa.eu Find medicine / Human Medicines (Veterinary Medicines) / European Public Assessment Reports
A conditional marketing authorisation (CMA) can be granted where the CHMP finds that, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, all of the following requirements are met:

- the benefit-risk balance of the medicinal product is positive;
- it is likely that the applicant will be in a position to provide comprehensive data;
- unmet medical needs will be fulfilled;
- the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required.

CMAs are **valid for one year**, on a renewable basis. The holder will be required to complete ongoing studies or to conduct new studies to confirm that the risk-benefit balance is positive. In addition, specific obligations may be imposed in relation to the collection of pharmaco-vigilance data.

The granting of a CMA allows medicines to reach patients with unmet medical needs earlier, and ensures that additional data on a product are generated, submitted, assessed and acted upon.

Applicants are encouraged to engage in early scientific dialogue with EMA and other stakeholders to discuss their development plan for a CMA (see 3.4.1).

For further guidance on the criteria for conditional marketing authorisation, justifications to be provided and the procedure to be followed, refer to the Commission Regulation (EC) No 507/2006 on the Commission website and to the respective CHMP guideline (EMA/CHMP/509951/2006, Rev.1) published on the EMA website.

### 6.14.3. Compassionate use

Compassionate use is a treatment option that allows the use of an unauthorised medicine. Under strict conditions, products in development can be made available to groups of patients with life-threatening, long-lasting or seriously debilitating illnesses which cannot be treated satisfactorily with any current authorised therapies and who cannot enter clinical trials. The medicine must be undergoing clinical trials or have entered the marketing authorisation application process and, while early studies will generally have been completed, its safety profile and dosage guidelines may not be fully established.

EMA provides recommendations through the CHMP for medicinal products that are eligible to be authorised via the centralised procedure (cf. section 6.1), but these do not create a legal framework. Compassionate use programmes are coordinated and implemented by Member States, which set their own rules and procedures.

Further information, in particular on how to request an opinion, is available on the EMA dedicated webpage.

### 6.14.4. Marketing authorisation under exceptional circumstances

In exceptional circumstances, a marketing authorisation can be granted subject to certain conditions, particularly concerning the safety of the product (‘marketing authorisation under exceptional circumstances’). Continuation of the authorisation will be linked to the annual reassessment of these conditions.

This can apply in cases where the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because:

- the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive evidence, or
- in the present state of scientific knowledge, comprehensive information cannot be provided, or
- it would be contrary to generally accepted principles of medical ethics to collect such information.

For further guidance on the conditions and procedures for the granting of a marketing authorisation under exceptional circumstances, refer to the EMA guidance for human medicinal products (EMA/357981/2005) published on the EMA website.

### 6.14.5. Adaptive pathways

The concept of adaptive pathways applies primarily to treatments in areas of high medical need where it is difficult to collect data via traditional routes and where large clinical trials would unnecessarily expose patients who are unlikely to benefit from the medicine. It is not a new regulatory route but builds on regulatory processes already in place within the existing EU legal framework in trying to design prospectively a development program which addresses those challenges, based on three principles:

---

6. APPLICATION FOR CENTRALISED MARKETING AUTHORISATION

1. Iterative development e.g.:

- Approval in stages, beginning with a restricted patient population then expanding to wider patient populations;
- Confirming the benefit-risk balance of a product, following a conditional approval based on early data (using surrogate endpoints) considered predictive of important clinical outcomes;

2. Gathering evidence through real-life use to supplement clinical trial data;

3. Early involvement of patients and health-technology-assessment bodies in discussions on a medicine’s development.

More information can be found on the EMA website208.

6.15. Marketing of a centrally authorised product in the Union

The marketing authorisation holder (MAH) of a centrally authorised product is legally obliged to inform EMA and the Member State(s) concerned (as applicable) of the dates of the actual marketing of the product in the respective Member States, taking into account the various presentations authorised. The MAH should notify EMA within 30 days of the initial placing on the market of the product within the EU.

Thereafter, any subsequent placing on the market or change in the marketing status should be reported through marketing status report that should be provided to EMA on a regular basis.

Withdrawn products

MAH of a centrally authorised product must notify EMA and the Member State(s) concerned as applicable of any of the following actions they intend to take together with the reason for it:

- Temporary or permanent cessation of marketing of a medicinal product;
- Suspension of marketing of a medicinal product;
- Withdrawal of a medicinal product from the market;
- Request for the withdrawal of a marketing authorisation;
- Non-application for the renewal of a marketing authorisation.

For further details on this provision for centrally authorised products, refer to the ‘Questions and Answers’ on this topic included in the EMA post-authorisation guidance209, which also provides details on obligations for notification of withdrawal from the market of nationally authorised products (national procedures, MRP, DCP).

Sunset Clause

Any authorisation, which is not followed by the actual marketing in at least one Member State in the European Union within three years after authorisation, will cease to be valid (so-called ‘sunset clause’). Similarly, when a product previously marketed in the European Union is no longer actually present on the market of any of the Member States of the European Union for three consecutive years, the authorisation will cease to be valid. However, the Commission in exceptional circumstances may grant exemptions from these provisions on duly justified public health grounds.

For more details on this provision, refer to the ‘list of questions and answers’ on this topic included in the EMA post-authorisation guidance210 on the EMA website.

7. RISK MANAGEMENT AND PHARMACOVIGILANCE
7. Risk management and pharmacovigilance

Pharmacovigilance, or the surveillance of the safety of a medicinal product during its life on the market, is extensively regulated by EU directives and regulations. EMA is co-ordinating pharmacovigilance at EU level with regards to medicinal products for human or veterinary use. EU legislation requires Member States to establish national pharmacovigilance systems to collect and evaluate information on adverse reactions to medicinal products or their side effects and to take appropriate action where necessary. It also requires marketing authorisation holders to report suspected adverse reactions to the authorities in certain formats and within specified timeframes. Applicants and marketing authorisation holders are also required to provide competent authorities with a description of their pharmacovigilance system and, where appropriate, of product-related risk management systems.

When a medicinal product is first authorised, the information available comes from experience in non-clinical testing and clinical trials. During the evaluation, its potential risks are weighed against its potential benefits based on what is known about the medicinal product at that time. Once it is placed on the market and used in a wider population, more information on its benefits and risks becomes available. Pharmacovigilance systems are designed to collect and continuously evaluate this information. If a medicinal product’s overall risk/benefit balance changes significantly for any reason, it may become necessary to vary, withdraw or suspend its use.

Strengthened pharmacovigilance legislation for medicinal products for human use (Regulation (EU) No 1235/2010\textsuperscript{211} and Directive 2010/84/EU\textsuperscript{212}) has been effective since July 2012, and had significant implications for applicants and holders of European Union marketing authorisations (see 7.2).

EMA together with the Member States has drawn up good pharmacovigilance practices (GVP)\textsuperscript{213} as a set of guidelines for the conduct of pharmacovigilance in the EU. The GVP replaces volume 9A of the rules governing medicinal products in the EU for medicinal products for human use (see section 7.1).

Volume 9B of the rules governing medicinal products in the European Union should be consulted in relation to medicinal products for veterinary use (see section 7.6).

7.1. Good pharmacovigilance practices (GVP)

Good pharmacovigilance practices (GVP)\textsuperscript{214} apply to marketing-authorisation holders (MAHs), EMA and national competent authorities. They cover medicines authorised centrally via the Agency as well as medicines authorised at national level.

The guidance on GVP contains 12 modules\textsuperscript{215}, each of which covers one major process in pharmacovigilance:

- **Module I: pharmacovigilance systems and their quality systems**
  - Establishment and maintenance of quality assured pharmacovigilance systems for MAHs, competent authorities and EMA, according to ISO general principles.

- **Module II: pharmacovigilance system master file (PSMF)**
  - Requirements for the PSMF, including its maintenance, content and associated submissions to competent authorities.

- **Module III: pharmacovigilance inspections**
  - Planning, conduct, reporting and follow-up of pharmacovigilance inspections in the EU and the role of the different parties involved.

- **Module IV: pharmacovigilance audits**
  - Planning and conduct of legally required audits, and the role, context and management of pharmacovigilance audit activity.

- **Module V: risk management systems**
  - Modular approach to risk management plans, aimed at characterising the safety profile of a medicinal product, and planning and implementing data collection and risk minimisation activities.

- **Module VI: management and reporting of adverse reactions to medicinal products**
  - Obligations of competent authorities, MAHs and EMA regarding the collection, data management and reporting of suspected adverse reactions associated with medicinal products authorised in the EU.

The reporting of emerging safety issues or suspected adverse reactions occurring in special situations.

Module VII: periodic safety update report (PSUR)
- Preparation, submission and assessment of PSURs and publication of PSUR-related documents.

Module VIII: post-authorisation safety studies (PASS)
- Transparency, scientific and quality standards of non-interventional PASSs conducted by MAHs.
- Procedures whereby a competent authority may impose an obligation to conduct a clinical or non-interventional study and the impact on the risk management system.

Module IX: signal management
- Structures and processes for signal management and their application in the setting of EU pharmacovigilance.

Module X: additional monitoring
- Requirements for product information for medicinal products which are new or present a specific safety concern, encouraging patients and healthcare professionals to report suspected adverse reactions and allowing for additional monitoring of the product safety profile.

Module XV: safety communication
- Communication and coordination of safety information in the EU.

Module XVI: risk minimisation measures: selection of tools and effectiveness indicators
- Educational programmes, controlled distribution systems and other risk minimisation measures, as well as indicators to measure their effectiveness.

Each GVP module should be consulted for further information on pharmacovigilance requirements for medicinal products for human use.

In addition to the module chapters, GVP contains chapters covering product- or population-specific considerations (e.g. on vaccines).

All GVP modules are grouped under the GVP webpage216.

7.2. Key aspects of the current EU pharmacovigilance system

This section highlights some of the important changes stemming from the 2010 pharmacovigilance legislation. A comprehensive overview of all the changes brought about by this legislation can be found on the EMA website217.

Establishment of the PRAC
The pharmacovigilance risk assessment committee (PRAC)218 has been established within EMA to provide scientific expertise in all matters relating to pharmacovigilance and to finalise pharmacovigilance assessments and recommendations on the safety of medicines at European level.

Pharmacovigilance system master file (PSMF)
MAHs are required to maintain a PSMF related to one or more products. The PSMF should be permanently available for submission or inspection by the national competent authority within seven days of a request. It should be located either at the site in the EU where the main pharmacovigilance activities of the marketing authorisation holder are performed or at the site in the EU where the qualified person responsible for pharmacovigilance (QPPV) operates. This file may be also stored in electronic form. The PSMF replaced the detailed description of the pharmacovigilance system (DDPS).

The applicant should submit electronically in the extended EudraVigilance medicinal product dictionary (XEVMPD) information on the PSMF location using the agreed format for an extended EudraVigilance product report message (XEVPRM). The XEVMPD will then assign a unique code (EVCODE) to the master file location, which can be noted in the application. Since 1 February 2016 companies no longer need to notify EMA (for centrally authorised products) or national competent authorities (for nationally authorised products) of changes to the QPPV or PSMF data by submitting a type IAIN variation. Companies should continue to ensure their entries in the Article 57 database for medicinal products for human use are up-to-date, including the QPPV and PSMF information.

218) http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000537.jsp&mid=WCO01ac058058cb18
The PSMF is not part of the MA dossier and is maintained independently from the MA. The MAA contains only a reference to the location and a summary of the applicant’s pharmacovigilance system. A list of the locations where PSMFs are kept and contact information for pharmacovigilance enquiries will be published by EMA.

GVP module II provides guidance on the requirements for the PSMF, including its maintenance, content and associated submissions to the competent authorities.

**Risk management plan (RMP)**

The RMP is a stand-alone document which summarises what is known about the safety of the product and discusses how the applicant/MAH will monitor and investigate further the safety profile of the product, and manage the risks associated with it. Guidance on RMP is provided in GVP module V. Additional guidance is available on the EMA website.

All applicants submitting an initial MAA are required to submit an RMP in the application dossier. An RMP (or an update, if one already exists) is also required where there is an application involving a significant change to an existing marketing authorisation or at the request of the Agency or national competent authority. Once a product has an RMP it needs to be updated throughout the life-cycle of the product. Summaries of the RMPs will be made public by the Agency.

SMEs are advised to contact the competent authorities to discuss the RMP in advance of its submission.

**Post-authorisation safety studies (PASS)**

The ability to require and enforce PASS has become part of the Agency’s toolkit for improving the benefit-risk monitoring of medicines. A PASS is a study of an authorised medicine which aims at identifying, characterising or quantifying a safety hazard, confirming the safety profile of the medicine, or measuring the effectiveness of risk management measures during its lifetime. Such studies provide information to support regulators in decision-making on the safety and benefit-risk profile of a medicine. A PASS may be imposed as a legal requirement on the conditions of a marketing authorisation (see 6.10), may be a requirement of an RMP or conducted voluntarily by an MAH. Guidance on PASS is provided in GVP module VIII.

Information on post-authorisation efficacy studies (PAES) is provided in section 6.11.

**Electronic submission of information on medicinal products under article 57(2)**

MAHs are required to submit electronically to the Agency information on all medicines authorised or registered in the EU pursuant to article 57(2) of Regulation (EC) 726/2004. The XEVMPD data-entry tool, also known as EVWEB (see section 7.5), should be used to submit the information.

The aim of the submission of data is to establish a complete inventory of all medicines authorised for use in the EU and EEA, including medicines authorised centrally via EMA and those authorised at national level. The Agency uses this information to support the analysis of data, regulatory activities and communication.

MAHs are required to submit information on new marketing authorisations within 15 calendar days from the date of notification of the granting of the marketing authorisation by the competent authority. This obligation applies to:

- nationally authorised medicinal products;
- centrally authorised medicinal products;
- medicinal products authorised through the mutual recognition procedure;
- medicinal products authorised through the decentralised procedure.

MAHs are also required to submit information concerning all medicinal products for which they hold a marketing authorisation in EEA countries outside the EU (i.e. Iceland, Liechtenstein and Norway), as the pharmacovigilance legislation is part of the EEA Agreement.

Information on any amendments to the terms of marketing authorisations following a variation, transfer, renewal, suspension, revocation or withdrawal must be notified to EMA no later than 30 calendar days from the date on which the amendments have been authorised.

For full details on the reporting requirements, see the legal notice and detailed guidance on the dedicated Guidance documents webpage.

**Periodic safety update reports**

Guidance on the content and format of a PSUR is published in GVP module VII. PSURs should present a critical analysis of the risk-benefit balance of the product taking into account new or emerging safety

---


information in the context of cumulative information on risk and benefits. Detailed listings of individual cases observed are no longer included, as these will have already been reported in EudraVigilance.

Once a medicinal product is authorised and marketed, PSURs have to be submitted immediately upon request and at the following time-points, unless other requirements have been laid down in the marketing authorisation: at least every six months during the first two years following the initial placing on the EU market and once a year for the following two years. Thereafter, the reports should be submitted at three-yearly intervals.

Prior to marketing, PSURs have to be submitted at 6 months intervals once the product is authorised and immediately upon request.

A single PSUR assessment procedure, with a recommendation from the PRAC, has been introduced for medicinal products authorised in more than one member state (i.e. products authorised through centralised, mutual recognition or decentralised procedures) and for products subject to different national marketing authorisations containing the same active substance or the same combination of active substances for which the PSUR submission dates and frequency have been harmonised in the EU. The approach is more proportionate to the risks posed by medicinal products. Thus, routine PSUR reporting is not necessary for products with low risk224, as defined in the marketing authorisation or the EURDS list.

The EURDS list, i.e. the list of EU reference dates and frequency of submission of PSURs (EURDS list225), provides information determining the need for PSURs and facilitating the harmonisation of data lock points and timelines for submission of PSURs. The EURDS list is the relevant tool for MAHs to plan PSUR-related activities, whilst noting that the competent authorities may still request PSURs at any time if deemed necessary.

Since June 2016, all PSUR submissions in the European Union should be uploaded in the PSUR repository226 which is available on the eSubmission website. Detailed instructions on what the repository is, how it functions and how to use it can be found on the same webpage.

Medicinal products subject to additional monitoring

The Agency maintains a public list of medicinal products containing new substances subject to additional monitoring.

These products are to be distinguished from others by a black symbol (i.e. the inverted black triangle ▼) and an explanatory sentence in the summary of product characteristics and the package leaflet. Further information is published on the EMA website227.

Medical literature monitoring

The Agency is required to monitor the scientific and medical literature to collect further reports of suspected adverse reactions, which will be entered into the EudraVigilance system. A defined list of publications228 for a defined list of active substances229 used in medicines is monitored and made public by the Agency. MAHs should not report cases arising from the literature monitored by the Agency, relating to the active substances subject to the monitoring. However they should continue to report cases they have identified from the literature not covered by that list.

Further guidance is available on a dedicated webpage230 and in the detailed guide regarding the monitoring of medical literature and the entry of relevant information into the EudraVigilance database by the European Medicines Agency231.

7.3. Reporting obligations


The safety reporting falls either under the scope of Directive 2001/20/EC and Regulation (EU) no 536/2014 for any clinical trials, or under the provisions set out in Directive 2001/83/EC and Regulation (EC) No 726/2004 for any non-interventional studies and spontaneous reporting. Suspected adverse reactions should not be reported under both regimes that are Directive 2001/20/EC and Regulation (EU) No 536/2014,
7. RISK MANAGEMENT AND PHARMACOVIGILANCE

as well as Regulation (EC) No 726/2004 and Directive 2001/83/EC as this creates duplicate reports. A detailed explanation of the different reporting rules is provided in chapter V1.C.1 of GVP module VI.

A data processing network and management system for reporting and evaluating suspected adverse reactions during the development and following the marketing authorisation of medicinal products in the European Economic Area (EEA), named "EudraVigilance", was launched in December 2001 (see Section 7.4).

7.3.1. Sponsors of clinical trials – reporting obligations

Sponsors of clinical trials are subject to the following reporting obligations, as laid down in the legislation, Directive 2001/20/EC, Regulation (EU) No 536/2014, and described in the "Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use ("CT-3")

All suspected unexpected serious adverse reactions (SUSARs) occurring in interventional clinical trials authorised in the EU have to be reported electronically to the competent authority(ies) and to EudraVigilance Clinical Trial Module (EVCTM) by the sponsor of the clinical trial.

This applies to all investigational medicinal products which are studied in interventional clinical trials conducted in the EEA and includes all SUSARs related to these medicinal products which occur either within or outside the EEA.

- for fatal and life-threatening SUSARs

The sponsor should report at least the minimum information as soon as possible and in any case no later than seven days after being made aware of the case of fatal and life-threatening SUSAR to EMA, the competent authority(ies) and the relevant ethics committee of the concerned Member State(s). If the initial report is incomplete, e.g. if the sponsor has not provided all the information/assessment within seven days, the sponsor should submit a completed report based on the initial information within an additional eight days. In this case, the receipt date should not be changed with regards to the initial report.

If significant new information on an already reported case is received by the sponsor, the clock starts again at day zero, i.e. the date of receipt of new information. This information should be reported as a follow-up report within 15 days.

- for non-fatal and non-life-threatening SUSARs

They must be reported to EMA, the competent authority(ies) and the relevant ethics committee of the concerned Member State(s) where the SUSARs occurred, as soon as possible but no later than 15 calendar days after the sponsor has first knowledge of the minimum criteria for expedited reporting. Further relevant follow-up information should be within 15 calendar days.

The sponsor must inform all investigators concerned of all relevant information about SUSARs. When feasible the information on SUSARs should be aggregated in a line listing of SUSARs in periods as warranted by the nature of the research project/clinical development project and the volume of SUSARs generated. This line listing should be accompanied by a concise summary of the evolving safety profile of the investigational medicinal product (IMP).

There may be cases where a SUSAR turns out to be fatal or life-threatening, whereas initially it was considered as non-fatal or not life-threatening. The non-fatal or non-life-threatening SUSAR should be reported as soon as possible, but within 15 days. The fatal or life-threatening SUSAR follow-up report should be made as soon as possible, but within a maximum of seven days after first knowledge of the reaction being fatal or life-threatening. In cases where a SUSAR turns out to be fatal or life-threatening, whereas initially it was considered as non-fatal or not life-threatening, while the initial report has not yet been submitted, a combined report should be created.
7.3.2. MAHs of medicinal products authorised in EEA - reporting obligations

Electronic reporting through Eudravigilance Post-authorisation Module (EVPM) is mandatory. The Agency receives all relevant information concerning suspected adverse reactions to medicinal products for human use which have been authorised in the EU.

The holder of the marketing authorisation for a medicinal product for human use should ensure that:

- **All suspected serious adverse reactions** to an authorised medicinal product occurring **within the Community**, regardless of the authorisation procedure, which a health-care professional or patient brings to the MAH’s attention are recorded and reported promptly to Member States within the territory of which the incident occurred, no later than 15 calendar days following the receipt of the minimum criteria for expedited reporting.

- **Any other suspected serious adverse reactions** to an authorised medicinal occurring **outside the Community** of which the MAH may reasonably be expected to be aware is recorded and promptly notified to the competent authority of Member States where the medicinal product is authorised and the Agency, and no later than 15 days following receipt of the minimum criteria for expedited reporting. This includes, but is not limited to reactions reported in the medical literature (see also section 7.2 above).

For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal product should be considered as a serious adverse reaction and such cases should be reported within 15 calendar days.

- **All suspected non-serious adverse reactions** to an authorised medicinal product within the Community have to be reported within 90 calendar days.

Marketing authorisation holders shall not refuse to consider reports of suspected adverse reactions received electronically or by any other appropriate means from patients and healthcare professionals.

The Agency may request specific pharmacovigilance data to be collected by the MAH. Any such data collected should be collated, assessed and submitted to the Agency for evaluation.

7.4. EudraVigilance

EudraVigilance is a data processing network and management system for reporting and evaluating suspected adverse reactions during development and following the marketing authorisation of medicinal products in the European Economic Area (EEA).

This network enables data to be exchanged efficiently between EMA, competent authorities, the marketing authorisation holders, and the sponsors of clinical trials in the EEA. EudraVigilance is a powerful tool for EMA and NCAs to monitor the safety of medicinal products and minimise potential risks related to suspected adverse reactions.

Taking into account the pharmacovigilance activities in the pre- and post-authorisation phase, EudraVigilance provides two reporting modules:

- **EudraVigilance clinical trial module (EVCTM)** to facilitate the electronic reporting of suspected unexpected serious adverse reactions (SUSARs) occurring in interventional clinical trials as required by Directive 2001/20/EC.

- **EudraVigilance post-authorisation module (EVPM)** designed for reporting post-authorisation individual case safety reports (ICSRs), pursuant to Regulation (EU) no 726/2004 and Directive 2001/83/EU.

7.5. EVWEB

In addition to automated message generation and processing, the EudraVigilance system also provides a web based tool to allow for a manual safety and acknowledgement message creation as well as generation of medicinal product reports via a web interface, called EVWEB.

It is specifically designed for SMEs and non-commercial sponsors, which do not have a fully ICH E2B(R2/3)-compliant pharmacovigilance system and/or ESTRI gateway in place. As such, it provides the necessary tools to allow SMEs to perform secure electronic reporting to EMA and all competent authorities in the EEA in accordance with the aforementioned legislation. It allows safety and acknowledgement messages to be sent and received in compliance with the latest ICH M2 standards. EVWEB also enables all messages to be saved locally and permits standardisation of message senders and receivers registered with the Agency as part of the EudraVigilance community. The same...
principles apply for medicinal product report messages. Any MAH, applicant or sponsor of a clinical trial in the EEA can use EVWEB. In order to use EVWEB, a computer with Internet Explorer versions 8 or 10 is required as well as internet access. To access the tool, a staff member of the company (or a nominated and registered representative organisation) is required to undertake and pass EudraVigilance training\(^{245}\), which is held at EMA every month and at various venues across the EEA. There is a fee reduction available to SMEs participating in these training sessions. Further information on how to register with EudraVigilance and the list of documents to be provided are detailed on the EudraVigilance website\(^{246}\).

Alternatively, SMEs may employ a contract research organisation (CRO) to perform the electronic transmission of ICSRs on their behalf. Some industry associations also offer an electronic reporting service to their member companies, and bilateral agreements with partner organisations are also permitted as long as they are captured within the EudraVigilance registration system and in the pharmacovigilance system master file.

All medical information in EudraVigilance & EVWEB is coded using MedDRA. MedDRA is a clinically validated international medical dictionary used by regulatory authorities and the regulated biopharmaceutical industry within the USA, the EU and Japan. MedDRA should be used for all regulatory activities especially reporting of ADRs, xEVMPD messages in accordance with article 57, PSURs and RMPs. MedDRA is free within EVWEB for small & micro-sized enterprises, but not for SMEs which are medium-sized\(^{247}\).

### 7.6. Pharmacovigilance for veterinary medicinal products

The MAHs of veterinary medicines are also required to follow-up on the safety and efficacy of their product during its life on the market, which includes, in addition to animal reactions, human reactions, possible environmental problems and investigations into the validity of the withdrawal period in case of products for food producing animals. The detailed requirements can be found in Volume 9B\(^ {248}\) of the rules governing medicinal products in the EU. These surveillance activities are captured under the term ‘pharmacovigilance’ and in general relate to 2 specific systems:

- **Periodic safety update report (PSUR)**

  The MAH must maintain detailed records of all adverse events within or outside the EU which are reported to it. Unless otherwise required, these reports need to be submitted to the Agency as part of the PSUR every six months until placing on the EU market and subsequently at least every six months during the first two years, once a year for the following two years and thereafter at three-yearly intervals. The PSUR includes an evaluation of the benefit-risk balance of the product.

  Further guidance on preparation and handling of PSURs is available in the post-authorisation question and answers section\(^ {249}\) of the EMA website.

- **15-day (or ‘expedited’) reporting**

  The MAH is obliged to report any serious adverse event in animals and all human adverse events occurring within or outside the EU (third country reports) and any suspected transmission via a medicinal product of any infectious agent outside the EU. These reports must be submitted promptly and no later than 15 days following the receipt of information to the Member State’s competent authority in which the event occurred or directly to the Agency in case of third country reports. The reporting occurs electronically using a central database system, called “EudraVigilance Veterinary” (EVVet)\(^ {250}\). Reports can be entered directly via the web-interface. The Agency, together with the Member States, monitors the information that becomes available in EVVet and will determine the need for regulatory action.

  Further guidance on the pharmacovigilance requirements for veterinary medicinal products is available at the EMA website\(^ {251}\).

---

245) For more information on the EudraVigilance training programme, please refer to http://ema-wip.ema.eu.int/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_00162.jsp&mid=WCOb01ac0580a11b


249) http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000064.jsp&mid=WCOb01ac05800250d5a


8. OTHER USEFUL INFORMATION
8. Other useful information

8.1. Information on medicinal products

The Community register of medicinal products is published on the European Commission’s website and contains a list of all medicinal products for human and veterinary use authorised via the centralised procedure and all designated orphan medicinal products for human use. The EMA’s website contains a vast array of additional product information that may interest SMEs, including:

- Public summaries of opinions for orphan designation
- Decisions on a Paediatric Investigation Plan
- CHMP & CVMP summaries of opinion

Note: The summary of opinion is replaced by the European public assessment report (see below) once the European Commission has taken its decision granting or refusing a marketing authorisation.

- European public assessment reports (EPARs)
- European public MRL assessment reports
- Information on marketing authorisation and marketing authorisation application withdrawals
- Product safety announcements
- Product opinions for non-EU use
- List of referred applications
- Information on herbal medicines for human use

A guide describing the information published by EMA on centrally and non-centrally authorised medicinal products for human use is also available on the EMA website (EMA/515416/2015).

8.2. Contact points at EMA

**SME office**

The SME office has been set up within the Agency to address the particular needs of smaller companies. The office aims to facilitate communication with SMEs through dedicated personnel within the Agency who will respond to practical or procedural enquiries, monitor applications, and organise workshops and training sessions for SMEs. Any comments on the content of this SME user guide should also be forwarded to the SME office.

*E-mail: sme@ema.europa.eu*
*Direct telephone: +44 (0)20 3660 8787*
*Fax: +44 (0)20 3660 5555*

**Advanced therapies and technologies**

General queries relating to advanced therapies and technologies can be sent to:

*E-mail: ITFsecretariat@ema.europa.eu*

**ATMP secretariat contact point:**

*E-mail: AdvancedTherapies@ema.europa.eu*

**Orphan designation**

Requests for further information on orphan designation applications and requests to set up a free pre-submission meeting should be sent to:

*E-mail: orphandrugs@ema.europa.eu*

**Scientific advice**

For queries relating to the procedure for scientific advice or to request a free pre-submission meeting, contact:

*For medicinal products for human use:*
*E-mail: ScientificAdvice@ema.europa.eu*

*For medicinal products for veterinary use:*
*E-mail: vetscientificadvice@ema.europa.eu*

---

**PRIME scheme**

Requests for information should be sent to:
Email: PRIME@ema.europa.eu

**Veterinary MUMS/limited market**

General queries / requests for further information on MUMS classification should be sent to:
E-mail: VetMUMSapplications@ema.europa.eu

**General enquiries**

The Agency publishes a wide range of documents, including press releases, guidance documents, annual reports and work programmes. These and other documents are available on our website at [www.ema.europa.eu](http://www.ema.europa.eu).
ANNEX 1
## Annex 1

### National provisions for SMEs applicable to the pharmaceutical sector (last update June 2016)

<table>
<thead>
<tr>
<th>Country</th>
<th>Human &amp; Veterinary medicines</th>
<th>National competent authority</th>
<th>Contact point</th>
<th>Existing national provisions for SMEs applicable to pharmaceutical sector</th>
</tr>
</thead>
</table>
| **AUSTRIA** | HUMAN & VET | AGES Austrian Medicines and Medical Devices Agency | Information on fee reductions for Veterinary medicinal products and Medicinal products produced in pharmacies: Dr. Peter Platzer  
Phone: +43 50 55 53 65 70  
E-mail: peter.platzer@ages.at | There are general provisions for fee reductions for the authorisation and life-cycle management for veterinary medicinal products and medicinal products produced in local pharmacies.  
More detailed information about the Austrian fee levels is available on the Agency’s website.[255](#) |
| **BELGIUM** | HUMAN & VET | Federal Agency for Medicines and Health Products | Phone: +32 2 528 40 68 or +32 2 528 41 27  
E-mail: sta@fagg-afmps.be infovet@fagg.be | No specific financial provisions.  
A specific mailbox was created at the agency for processing SME related questions.  
The agency is member of the European Innovation Offices Network coordinated by EMA which represents an important interface between national SMEs, academic innovators and the EU regulatory system. |
| **BULGARIA** | HUMAN | Bulgarian Drug Agency | Phone: +359 28 90 35 55  
E-mail: bda@bda.bg | No specific provisions for SMEs for human medicines. |
| **CROATIA** | HUMAN | Agency for Medicinal Products and Medical Devices | Contact point:  
Maja Lovrek  
E-mail: maja lovrek@halmed.hr  
Phone: + 385 1 4884 136 | No specific provisions. |

<table>
<thead>
<tr>
<th>Country</th>
<th>Sector</th>
<th>Contact Details</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VET</strong></td>
<td><strong>CYPRUS</strong></td>
<td><strong>Ministry of Health Pharmaceutical Services</strong>&lt;br&gt;7 Larnacos Avenue&lt;br&gt;1475 Lefkosia&lt;br&gt;Cyprus&lt;br&gt;<a href="http://www.moh.gov.cy/moh/moh.nsf/index_en/index_en?OpenDocument">http://www.moh.gov.cy/moh/moh.nsf/index_en/index_en?OpenDocument</a></td>
<td>Mr. Ioannis Kkolos&lt;br&gt;Pharmaceutical Services&lt;br&gt;Phone: +357 22 40 71 32&lt;br&gt;E-mail: <a href="mailto:jkkolos@phs.moh.gov.cy">jkkolos@phs.moh.gov.cy</a>&lt;br&gt;The Cyprus Research Promotion Foundation is an independent establishment that promotes scientific and technological research in Cyprus through grant schemes of up to 800k€. Its main measures include three packages: measures on health research, measures on SME research and measures relating to the development of research infrastructures.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maria Papaprodromou&lt;br&gt;Veterinary Services&lt;br&gt;Phone: +357 22 80 51 13&lt;br&gt;E-mail: <a href="mailto:MaPapaprodromou@vs.moa.gov.cy">MaPapaprodromou@vs.moa.gov.cy</a></td>
<td>The Cyprus’ Research Promotion Foundation actions and initiatives in the Health and SMEs Research sector cover also the Veterinary field. In accordance to article 6 of the VMP (Fees) Regulations of 2006 and 2012, the Veterinary Medicinal Products Council acting as the VMPs Competent Authority can, in the case of VMPs which are deemed necessary for public health and whose volume of sales is of such quantity that it is not expected for their circulation cost to be covered, to waive the applicant from the obligation to pay whole or part of the assessment and marketing authorization fees.</td>
</tr>
<tr>
<td></td>
<td><strong>CZECH REPUBLIC</strong></td>
<td><strong>State Institute for Drug Control</strong>&lt;br&gt;Srobárova 48&lt;br&gt;100 41 Praha 10&lt;br&gt;Czech Republic&lt;br&gt;www.sukl.cz</td>
<td>Phone: +420 27 21 85 11 1&lt;br&gt;E-mail: <a href="mailto:posta@sukl.cz">posta@sukl.cz</a>&lt;br&gt;Under government decree no. 327/2013 coll., SMEs are eligible to 50% reduction of fees charged by the State Institute for Drug Control (SUKL) for expert activities and annual fees. All applicants meeting requirements laid down by decree No 327/2013 are granted the reduction of fees.</td>
</tr>
<tr>
<td></td>
<td><strong>VET</strong></td>
<td><strong>Ústav pro státní kontrolu veterinárních biopreparátu a léčiv</strong>&lt;br&gt;Hudcova 56a&lt;br&gt;621 00 Brno - Medlánky&lt;br&gt;Czech Republic&lt;br&gt;www.uskvbl.cz</td>
<td>Phone: 420 54 12 10 02 20 24&lt;br&gt;E-mail: <a href="mailto:uskvbl@uskvbl.cz">uskvbl@uskvbl.cz</a>&lt;br&gt;No specific provisions.</td>
</tr>
</tbody>
</table>
### ANNEX 1

<table>
<thead>
<tr>
<th>Country</th>
<th>Sector</th>
<th>Name</th>
<th>Address</th>
<th>Phone</th>
<th>E-mail</th>
<th>Fee Exemptions</th>
<th>Additional Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DENMARK</strong></td>
<td>HUMAN &amp; VET</td>
<td>Danish Medicines Agency</td>
<td>Axel Heides Gade 1 2300 Copenhagen Denmark <a href="http://www.LMST.dk">www.LMST.dk</a></td>
<td>Phone: +45 44 88 95 95 E-mail: <a href="mailto:dkma@dkma.dk">dkma@dkma.dk</a></td>
<td>The national fee structure and service/administrative procedures are adjusted to the special needs of Danish SME enterprises. In addition, fee exemptions are also available in specific circumstances e.g. that the medicinal product is essential to the patient's treatment. For more detailed information about the Danish fee levels, a total list of current fees can be found on the Danish Medicines Agency website under the heading medicinal products, fees payable. In addition, the website contains information on how to obtain administrative and procedural assistance, and information about the supervision of medicinal products and medical devices, including how to obtain scientific advice.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ESTONIA</strong></td>
<td>HUMAN &amp; VET</td>
<td>State Agency of Medicines</td>
<td>1 Nooruse Street 50411 Tartu Estonia <a href="http://www.ravimiamet.ee">www.ravimiamet.ee</a></td>
<td>Phone: +372 73 74 14 0 E-mail: <a href="mailto:info@ravimiamet.ee">info@ravimiamet.ee</a> Mrs. Kaili Lellep Phone: +372 73 74 14 0 E-mail: <a href="mailto:kaili.lellep@ravimiamet.ee">kaili.lellep@ravimiamet.ee</a></td>
<td>Support of Enterprise and State Loan Guarantees Act (RT I 2003, 18, 96 as amended) contains provisions for SMEs in Estonia, applicable also to the pharmaceutical sector. The act sets out the bases, principles and organisation of state support for enterprises and the grant of state guarantees for loan agreements and leasing contracts.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FINLAND</strong></td>
<td>HUMAN &amp; VET</td>
<td>Finnish Medicines Agency</td>
<td>P.O. Box 55 (Mannerheimintie 103b, Helsinki) 00034 FIMEA Finland <a href="http://www.fimea.fi">http://www.fimea.fi</a></td>
<td>Phone: +358 29 522 3341</td>
<td>General and specific regulatory advice may be requested by SMEs. Fee exemptions are available for scientific advice.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>FRANCE</strong></td>
<td>HUMAN</td>
<td>Agence nationale de sécurité du médicament et des produits de santé (ANSM)</td>
<td>143-147 bd Anatole France 93285 Saint-Denis CEDEX France <a href="http://www.an">www.an</a> sm.sante.fr</td>
<td>Phone: +33 1 55 87 30 00 Dr François Cuenot E-mail: <a href="mailto:innovation@ansm.sante.fr">innovation@ansm.sante.fr</a></td>
<td>No specific financial provisions for SMEs applicable to human health products. ANSM has established procedures in order to help the development of innovative human health products: - early discussion with ANSM - scientific advice - pre-submission procedure for clinical trials These procedures are free of charge for all structures, including SMEs.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

257) http://ansm.sante.fr/L-ANSM2/Guichet-Innovation
258) http://ansm.sante.fr/L-ANSM2/Avis-scientifique-de-medicament
259) http://ansm.sante.fr/var/ansm_site/storage/original/application/748155fca2cdeb07c5cefe0a57da8ec5.pdf
<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>Organization</th>
<th>Address</th>
<th>Phone</th>
<th>E-mail</th>
<th>Fee Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>VET</td>
<td>VETERINARY</td>
<td>Agence Nationale du Médicament Vétérinaire</td>
<td>Anses-ANMV 8 rue Claude Bourgelat Parc d'Activités de la Grande Marche CS 70611 35306 Fougères France <a href="http://www.anses.fr">www.anses.fr</a></td>
<td>+33 2 99 94 78 71</td>
<td><a href="mailto:sylvie.goby@anses.fr">sylvie.goby@anses.fr</a></td>
<td>Specific fees for marketing authorisation for MUMS, herbal veterinary medicinal products and homeopathic veterinary medicinal products are available. The annual fees are proportionate to the turnover of the company for each medicinal product. There is no fee where the turnover is less than 50,000 euros and progressive annual fee apply up to 1,000,000 euros (article D. 5141-60 of public health code).</td>
</tr>
<tr>
<td>GERMANY</td>
<td>HUMAN</td>
<td>Federal Institute for Drugs and Medical Devices (BfArM)</td>
<td>Kurt-Georg Kiesinger-Allee 3 53175 Bonn Germany <a href="http://www.bfarm.de">www.bfarm.de</a></td>
<td>+49 228 99 307 3958</td>
<td><a href="mailto:peggy.beinlich@bfarm.de">peggy.beinlich@bfarm.de</a></td>
<td>An Innovation Office will be introduced soon. SME fee reductions are available for licensing activities: according to art. 3, paragraph 2 of the German regulation on licensing fees for medicinal products, the fee can be reduced by up to 50% if justified by the related operating expense of the authority and the relevance, economic value or other benefit for the applicant.</td>
</tr>
<tr>
<td>HUMAN - SERA, VACCINES, BLOOD PREPARATIONS</td>
<td>HUMAN</td>
<td>Paul Ehrlich Institut</td>
<td>Federal Institute for Vaccines and Biomedicines Paul Ehrlich Str. 51-59 63225 Langen Germany <a href="http://www.pei.de">www.pei.de</a></td>
<td>+49 61 03 77 10 12</td>
<td><a href="mailto:innovation@pei.de">innovation@pei.de</a></td>
<td>The Paul-Ehrlich-Institut has established an innovation office to coordinate regulatory and scientific advice especially for SMEs and academic institutions with the focus on ATMPs. The office provides an «all-in-one» solution, co-ordinating advice as well as providing a liaison to German Federal State Authorities and HTA institutions as well as to EMA. Information and details about the innovation office of the PEI can be found on the Paul-Ehrlich-Institut website. For authorisations and all other public services, applicants can apply for a fee reduction up to 75% by demonstrating a special public interest and a lack of profit due to limited use.</td>
</tr>
</tbody>
</table>
### VET

**Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)**  
Mauerstr. 39 - 42  
10117 Berlin  
Germany  
www.bvl.bund.de  

**Contact Information:**  
Phone: +49 30 18 44 57 100  
E-mail: poststelle@bvl.bund.de  
Dr. Angelika Schadowinkel-Scherkl  
Ref. 301  
E-mail: 301@bvl.bund.de  

- **Information:** In addition to the provision mentioned by BfArM, the German Fees Ordinance (AMGKosTV) offers the possibility to reduce the standard fees normally charged for a marketing authorisation by up to 75% (section 3 sub-section 2 of the Fees Ordinance). This requires an application and only applies to products for which the expenses outweigh the expected profit and public interest can be identified (no alternative) or which will be used in rare cases.  

- **Notes:** If the authorisation is refused section 2 of the Fee Ordinance provides for a mandatory reduction of 25%. A further reduction or easement from charging a fee is possible if justified in particular cases. There is no possibility for a fee deferral.

### GREECE

**HUMAN & VET**  
**EOF – National Drug Organisation**  
Mesogion Avenue 284  
Holarqos  
Athens 15562  
Greece  
www.eof.gr  

**Contact Information:**  
Phone: +30 2132040297  
E-mail: relation@eof.gr  

- **No specific provisions.**

### HUNGARY

**HUMAN**  
**National Institute of Pharmacy and Nutrition**  
Zrínyi u. 3.  
1051 Budapest  
Hungary  
http://ogyei.gov.hu  

**Contact Point:**  
Csilla Pozsgay MD  
Director general  
Phone: +36 18 86 93 07  
E-mail: pozsgay.csilla@ogyei.gov.hu  

- **No specific provisions.**

### VET

**National Food Chain Safety Office**  
Directorate of Veterinary Medicines  
Szálás utca 8.  
1107 Budapest  
Hungary  
http://www.nebih.gov.hu  

**Contact Information:**  
Dr. Gábor Kulcsár  
Phone: +36 14 33 03 30  
Email: kulcsarg@nebih.gov.hu  

- **No specific provisions.**

### IRELAND

**HUMAN & VET**  
**Health Products Regulatory Authority**  
Earlsfort Centre  
Earlsfort Terrace  
Dublin 2  
Ireland  
www.hpра.ie  

**Contact Information:**  
Information on fees is available from the HPRA website: www.hpра.ie  
Phone: +353 16 76 49 71  
E-mail: info@hpра.ie  
Specific queries on service item fees can be directed to accounts@hpра.ie  

- **Notes:** There is a service item fee (reduced fee) that relates to the market segment/use of the product (not to the size of the individual pharmaceutical company).
According to Article 4, paragraph 6, of Decree of the Ministry of Health of 29 March 2012, no. 53 (amendment to the regulation and operation of the Italian Medicines Agency), which was adopted in order to enforce the provisions of article 17, paragraph 10, of Decree-law, 06 July 2011, no. 98, for SMEs and public institutions, the amounts of annual fees are reduced by 25%.

On the basis of the aforementioned Article 4, the same reduction is applicable to services that AIFA may provide in favour of third parties (i.e.: a. national activities of scientific advice; b. training and continuing education for industry professionals; c. analysis of research and field studies; d. publishing activities).

As regards the fees due for administrative variations of marketing authorizations and variations related to the change of production site, Article 158, paragraph 12, of Legislative Decree 24 April 2006, No. 219 (as amended by Article 9-duodocies, paragraph 5, of Decree-law 19 June 2015, No. 78) provides that the Health Minister, in accordance with AIFA, shall adopt a decree providing a 25% reduction to SMEs. The above-mentioned decree is currently under discussion.

There is a specific provision for exemption from the annual fee for post-registration surveillance of the relevant medicine unless the turnover of the said medicine for the previous calendar year exceeded EUR 2134,31.

This provision ensures the availability of medicines which are manufactured or distributed in a limited amount.

Medicines, which are not widely marketed within year of taxation, can be waived from yearly post authorisation fee.
**ANNEX 1**

<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>Organization</th>
<th>Address</th>
<th>Phone/Email</th>
<th>Notes</th>
</tr>
</thead>
</table>
| **LITHUANIA**    | HUMAN  | State Medicines Control Agency                                                | Žirmūnų str. 139A 09120 Vilnius Lithuania                                                 | Phone: +370 5 263 92 64 Mrs Irena Vaketaite  
|                  |        |                                                                              |                                                                              | Head of Inspections Unit  
|                  |        |                                                                              |                                                                              | Phone: +370 5 263 98 91  
|                  |        |                                                                              |                                                                              | E-mail: irenavaketaite@vvkt.lt                                               | No specific provisions.                   |
|                  | VET    | National Food and Veterinary Risk Assessment Institute                        | J. Kairiūkščio str. 10 08409 Vilnius Lithuania                                           | Phone: +370 5 278 04 84  
|                  |        |                                                                              |                                                                              | E-mail: nmvrvi@vet.lt  
|                  |        |                                                                              |                                                                              | Dr Mačiulskis Petras Deputy Director  
|                  |        |                                                                              |                                                                              | Phone: +370 5 278 04 84  
|                  |        |                                                                              |                                                                              | E-mail: pmaciuiskis@vet.lt                                                | No specific provisions.                   |
| **LUXEMBOURG**   | HUMAN & VET | Direction de la Santé             | Villa Louvigny Division de la Pharmacie et des Medicaments Allée Marconi 2120 Luxembourg | Human  
|                  |        |                                                                              |                                                                              | E-mail: luxdpm@ms.etat.lu  
|                  |        |                                                                              |                                                                              | Veterinary  
|                  |        |                                                                              |                                                                              | Email: luxvet@ms.etat.lu                                               | No specific provisions.                   |
| **MALTA**        | HUMAN  | Medicines Authority                                                           | 203, Level 3 Rue D’Argens Gżira GZR 03 Malta                                            | Phone: +356 23 43 90 00  
|                  |        |                                                                              |                                                                              | E-mail: info.medicinesauthority@gov.mt  
|                  |        |                                                                              |                                                                              | Malta Enterprise  
|                  |        |                                                                              |                                                                              | Phone: +356 2542 0000  
|                  |        |                                                                              |                                                                              | E-mail: info@maltaenterprise.com                                          | Companies engaged in the production of pharmaceuticals (including the packaging of such products) qualify for assistance and incentives. This is subject to approval of the activity by Malta Enterprise – the Maltese entity responsible for foreign direct investment, internationalisation of companies and the promotion of entrepreneurship and business start-ups. Further information is available on the Malta Enterprise website: http://support.maltaenterprise.net/ |
|                  | VET    | Ministry for Resources and Rural Affairs                                       | Fish and Farming Regulation and Control Division The Abattoir, Albert Town Marsa MRS 1123 Malta | Phone: +356 2590 5100  
|                  |        |                                                                              |                                                                              | Email: vafd.mrra@gov.mt  
|                  |        |                                                                              |                                                                              | Malta Enterprise  
|                  |        |                                                                              |                                                                              | Phone: +356 2542 0000  
<p>|                  |        |                                                                              |                                                                              | E-mail: <a href="mailto:info@maltaenterprise.com">info@maltaenterprise.com</a>                                          | See under Human.                          |</p>
<table>
<thead>
<tr>
<th>Country</th>
<th>Sector</th>
<th>Organisation</th>
<th>Address</th>
<th>Phone</th>
<th>Email</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NETHERLANDS</td>
<td>HUMAN &amp; VET</td>
<td>College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board</td>
<td>Kalvermarkt 53, P.O.Box 16229, 2511 CB Den Haag, The Netherlands, <a href="http://www.cbg-meb.nl">www.cbg-meb.nl</a></td>
<td>+31 70 35 67 40 0</td>
<td><a href="mailto:info@cbg-meb.nl">info@cbg-meb.nl</a></td>
<td>No specific provisions.</td>
</tr>
<tr>
<td>POLAND</td>
<td>HUMAN &amp; VET</td>
<td>Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</td>
<td>Al. Jerozolimskie 181c, 02-222 Warsaw, Poland, <a href="http://bip.urpl.gov.pl/pl">http://bip.urpl.gov.pl/pl</a></td>
<td>+48 22 49 21 10 0</td>
<td><a href="mailto:bip@urpl.gov.pl">bip@urpl.gov.pl</a></td>
<td>No specific provisions.</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>HUMAN</td>
<td>INFARMED, I.P. – Autoridade Nacional do Medicamento e Produtos de saúde, I.P.</td>
<td>Parque de Saúde de Lisboa, Avenida do Brasil n°. 53 – 1749-004 Lisboa, Portugal, <a href="http://www.infarmed.pt">www.infarmed.pt</a></td>
<td>+351 21 798 7316</td>
<td><a href="mailto:garc@infarmed.pt">garc@infarmed.pt</a></td>
<td>INFARMED, I.P. provides scientific advice to applicants developing medicinal products, medical devices and cosmetic products. Advice is provided on premises and GMP compliance, scientific and regulatory issues related to pre-submission and post-marketing activities. These activities are provided to any company or academic institution regardless of origin or size. In general, for pharmaceutical companies, scientific advice requests are subject to payment of fees in accordance with Nos. 12 and 13 of the annex to portaria No. 377/2005 of 04 April (available at INFARMED’s website). Special provisions exist to grant fee exemption or a fee reduction on grounds of public health and/or company category (SMEs). For SMEs that do not have yet products on the market, academic or hospital institutions, a full exemption is granted. Applicants developing cosmetics and medical devices are also exempted.</td>
</tr>
<tr>
<td>Country</td>
<td>Sector</td>
<td>Agency Name</td>
<td>Contact Person</td>
<td>Fees and Regulations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>--------</td>
<td>----------------------------------------------------------------------------</td>
<td>-----------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>VET</td>
<td>DGAV – Direção-Geral de Alimentação e Veterinária</td>
<td>Prof. Álvaro Pegado Mendonça</td>
<td>Portaria nº. 317-A/2000 of 31 May and the SIPIE (IAPMEI) also applies to the veterinary sector. DGAV provides scientific and regulatory advice to applicants, during the initial development stages of veterinary medicinal products (pre-submission) and also in the post-marketing phase. Scientific and regulatory advice concerning a MRP or DCP application is subject to payment of fees in accordance with nº. 21 of the annex to Portaria nº. 27/2011 of 10 January. Upon duly justified request, a fee reduction may be granted namely in case of lack of availability and limited use of veterinary medicines in accordance with nº. 5, of article 2º, (available at DGAV’s website).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ROMANIA</td>
<td>HUMAN</td>
<td>National Agency for Medicines and Medical Devices</td>
<td>Mrs Victorita Ivascu</td>
<td>No specific provisions.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VET</td>
<td>Institutul pentru Controlul Produselor Biologice si Medicamentelor de Uz Veterinar</td>
<td></td>
<td>No specific provisions.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLOVAK REPUBLIC</td>
<td>HUMAN</td>
<td>State Institute for Drug Control</td>
<td>Mgr Diana Madaraszova</td>
<td>No specific provisions.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>VET</td>
<td>Institute for State Control of Veterinary Biologicals and Medicaments</td>
<td></td>
<td>No specific provisions.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country</td>
<td>Type</td>
<td>Organization</td>
<td>Contact Person</td>
<td>Notes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>Human &amp; Vet</td>
<td>Agency for Medicinal Products and Medical Devices of the Republic of Slovenia</td>
<td>Mrs Barbara Kovač</td>
<td>No specific provisions.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phone: +386 8 2000 500</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E-mail: <a href="mailto:Barbara.Kovac@jazmp.si">Barbara.Kovac@jazmp.si</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>Human &amp; Vet</td>
<td>Agencia Española del Medicamento y Productos Sanitarios</td>
<td>Ms Belén Crespo Sánchez-Eznarriaga</td>
<td>No specific provisions.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phone: +34 91 822 50 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E-mail: <a href="mailto:sdaem@aemps.es">sdaem@aemps.es</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>Human &amp; Vet</td>
<td>Medical Products Agency</td>
<td>Phone: +46 18 17 46 00</td>
<td>The Innovation Support Office assists SMEs and academia in the regulatory and scientific areas.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E-mail: <a href="mailto:registrar@mpa.se">registrar@mpa.se</a></td>
<td>Scientific advice may be requested for medicinal products irrespective of subsequent choice of procedure for approval.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SME-guide:</td>
<td>The Medical Products Agency has established a web area, “the SME-guide”, where users are guided through web pages containing information related to the regulatory field.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><a href="http://www.lakemedelsverket.se/malgrupp/Foretag/SME-guiden/">http://www.lakemedelsverket.se/malgrupp/Foretag/SME-guiden/</a></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Innovation Support Office Brita Sjöström Torbjörn Arvidsson</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Human</td>
<td>Medicines and Healthcare Products Regulatory Agency (MHRA)</td>
<td>Ms Kirsten Padgham</td>
<td>The MHRA offers a number of easements to SMEs to aid their ability to pay the fee due. These easements include:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Policy Division</td>
<td>• 25% of the application fee for a new active substance at the time of the application with the remaining 75% payable within 30 days of the marketing authorisation being determined;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E-mail:</td>
<td>• 50% of most other marketing authorisation applications fee at the time of application and 50% within 30 days of the application being determined;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><a href="mailto:kirsten.padgham@mhra.gsi.gov.uk">kirsten.padgham@mhra.gsi.gov.uk</a></td>
<td>• 25% of the fee relating to outgoing mutual recognition applications for new active substances at time of application and 75% once that procedure has been completed;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mrs Tahni Rush Finance Division</td>
<td>• 50% for most other outgoing mutual recognition applications and 50% once that procedure has been completed;</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E-mail: <a href="mailto:tahni.rush@mhra.gsi.gov.uk">tahni.rush@mhra.gsi.gov.uk</a></td>
<td>• 50% at the time of applications for manufacturers’ or wholesale dealers’ licences with 50% payable when the applications have been determined.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The 50% 'rule' also applies to the payment of:

- all inspection fees, including those relating to registrations for traditional herbal medicines;
- applications for traditional herbal medicines registrations and applications for complex variations to traditional herbal registrations;
- applications for registrations under the homeopathic registration schemes.

In addition to these easements, there are some lower fees that reflect the size of a company. For example, wholesale dealers meeting certain criteria including low turnover of licensed products, are eligible for lower application, inspection and annual fees. Also the annual fees for marketing authorisations are set with a sliding scale relating to turnover of the product.

The MHRA offer pre-application scientific advice meetings at which companies can seek advice on the development of a product, but there is currently no easement of payment for fees relating to these meetings. Companies must meet certain criteria and need to make applications in writing.
The Veterinary Medicines Regulations includes some easements applicable to SMEs: Inspection fees for manufacturing authorisation holders’ sites are based on the size of a company. Sites at which fewer than 10 relevant persons are employed pay the lowest inspection fees.

There are reduced inspection fees for wholesale dealer authorisation holders that meet certain criteria e.g. those that only distribute ‘lower risk’ products or those whose annual turnover is less than a specified amount.

There are reduced application fees and annual fees for manufacturing authorisation holders’ and wholesale dealer authorisation holders that meet certain criteria e.g. those that only distribute ‘lower risk’ products or those whose annual turnover is less than a specified amount.

In addition to these easements, the annual fee for marketing authorisations is adjusted to reflect the size and the activity of a company, and is based on turnover and numbers of marketing authorisations held at any time during the previous calendar year.

The VMD offers free meetings at which companies can seek advice on all topics related to the registration of products, including the development of a product. This free advice is available to all companies irrespective of size.
## ANNEX 1

### Appendix

**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADI</td>
<td>ACCEPTABLE DAILY INTAKE</td>
</tr>
<tr>
<td>ADR</td>
<td>ADVERSE DRUG REACTION</td>
</tr>
<tr>
<td>ASMF</td>
<td>ACTIVE SUBSTANCE MASTER FILE</td>
</tr>
<tr>
<td>API</td>
<td>ACTIVE PHARMACEUTICAL INGREDIENT</td>
</tr>
<tr>
<td>ATMPs</td>
<td>ADVANCED THERAPY MEDICINAL PRODUCTS</td>
</tr>
<tr>
<td>AUC</td>
<td>AREA UNDER THE CURVE</td>
</tr>
<tr>
<td>AWU</td>
<td>ANNUAL WORK UNIT</td>
</tr>
<tr>
<td>BfArM</td>
<td>BUNDESINSTITUT FÜR ARZNEIMITTEL UND MEDIZINPRODUKTE</td>
</tr>
<tr>
<td>CAT</td>
<td>COMMITTEE FOR ADVANCED THERAPIES</td>
</tr>
<tr>
<td>CCI</td>
<td>COMMERCIALLY CONFIDENTIAL INFORMATION</td>
</tr>
<tr>
<td>CD-ROM</td>
<td>COMPACT DISC – READ ONLY MEMORY</td>
</tr>
<tr>
<td>Cdt</td>
<td>CENTRE FOR TRANSLATION</td>
</tr>
<tr>
<td>CEP</td>
<td>CERTIFICATE OF SUITABILITY</td>
</tr>
<tr>
<td>CHMP</td>
<td>COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE</td>
</tr>
<tr>
<td>CMA</td>
<td>CONDITIONAL MARKETING AUTHORISATION</td>
</tr>
<tr>
<td>COMP</td>
<td>COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS</td>
</tr>
<tr>
<td>CRO</td>
<td>CONTRACT RESEARCH ORGANISATION</td>
</tr>
<tr>
<td>CTA</td>
<td>CLINICAL TRIAL APPLICATION</td>
</tr>
<tr>
<td>CTD</td>
<td>COMMON TECHNICAL DOCUMENT</td>
</tr>
<tr>
<td>CTFG</td>
<td>CLINICAL TRIALS FACILITATION GROUP</td>
</tr>
<tr>
<td>CTR</td>
<td>CLINICAL TRIALS REGISTER</td>
</tr>
<tr>
<td>CVMP</td>
<td>COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE</td>
</tr>
<tr>
<td>DDPS</td>
<td>DETAILED DESCRIPTION PHARMACOVIGILANCE SYSTEM</td>
</tr>
<tr>
<td>DSUR</td>
<td>DEVELOPMENT SAFETY UPDATE REPORT</td>
</tr>
<tr>
<td>DVD</td>
<td>DIGITAL VERSATILE DISC</td>
</tr>
<tr>
<td>EC</td>
<td>EUROPEAN COMMISSION</td>
</tr>
<tr>
<td>e-CTD</td>
<td>ELECTRONIC COMMON TECHNICAL DOCUMENT</td>
</tr>
<tr>
<td>EDQM</td>
<td>EUROPEAN DIRECTORATE FOR QUALITY OF MEDICINES AND HEALTH CARE</td>
</tr>
<tr>
<td>EEA</td>
<td>EUROPEAN ECONOMIC AREA</td>
</tr>
<tr>
<td>EEC</td>
<td>EUROPEAN ECONOMIC COMMUNITY</td>
</tr>
<tr>
<td>EMA</td>
<td>EUROPEAN MEDICINES AGENCY</td>
</tr>
<tr>
<td>EnprEMA</td>
<td>EUROPEAN NETWORK OF PAEDIATRIC RESEARCH AT THE EUROPEAN MEDICINES AGENCY</td>
</tr>
<tr>
<td>EPAR</td>
<td>EUROPEAN PUBLIC ASSESSMENT REPORT</td>
</tr>
<tr>
<td>EPL</td>
<td>EMA PRODUCT LEAD</td>
</tr>
<tr>
<td>ERA</td>
<td>ENVIRONMENTAL RISK ASSESSMENT</td>
</tr>
<tr>
<td>ESTRI</td>
<td>ELECTRONIC STANDARDS FOR THE TRANSFER OF REGULATORY INFORMATION</td>
</tr>
<tr>
<td>EU</td>
<td>EUROPEAN UNION</td>
</tr>
<tr>
<td>EudraCT</td>
<td>EUROPEAN CLINICAL TRIALS DATABASE</td>
</tr>
<tr>
<td>EudraGMP</td>
<td>EUROPEAN DATABASE ON MANUFACTURING AND IMPORT AUTHORISATIONS AND GOOD MANUFACTURING PRACTICE</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>EURDS</td>
<td>EUROPEAN UNION REFERENCE DATES</td>
</tr>
<tr>
<td>EVCODE</td>
<td>EUDRAVIGILANCE CODE</td>
</tr>
<tr>
<td>EVCTM</td>
<td>EUDRAVIGILANCE CLINICAL TRIAL MODULE</td>
</tr>
<tr>
<td>EVPM</td>
<td>EUDRAVIGILANCE POST-AUTHORISATION MODULE</td>
</tr>
<tr>
<td>EVVET</td>
<td>EUDRAVIGILANCE VETERINARY</td>
</tr>
<tr>
<td>EWWEB</td>
<td>EUDRAVIGILANCE WEB-BASED TOOL</td>
</tr>
<tr>
<td>FDA</td>
<td>FOOD AND DRUG ADMINISTRATION</td>
</tr>
<tr>
<td>GCP</td>
<td>GOOD CLINICAL PRACTICE</td>
</tr>
<tr>
<td>GDP</td>
<td>GOOD DISTRIBUTION PRACTICE</td>
</tr>
<tr>
<td>GLP</td>
<td>GOOD LABORATORY PRACTICE</td>
</tr>
<tr>
<td>GMOs</td>
<td>GENETICALLY MODIFIED ORGANISMS</td>
</tr>
<tr>
<td>GMP</td>
<td>GOOD MANUFACTURING PRACTICE</td>
</tr>
<tr>
<td>GVP</td>
<td>GOOD PHARMACOVIGILANCE PRACTICE</td>
</tr>
<tr>
<td>HTA</td>
<td>HEALTH TECHNOLOGY ASSESSMENT</td>
</tr>
<tr>
<td>ICH</td>
<td>INTERNATIONAL COUNCIL FOR HARMONISATION</td>
</tr>
<tr>
<td>ICTRIP</td>
<td>INTERNATIONAL CLINICAL TRIALS REGISTRY PLATFORM</td>
</tr>
<tr>
<td>IMP</td>
<td>INVESTIGATIONAL MEDICINAL PRODUCT</td>
</tr>
<tr>
<td>INN</td>
<td>INTERNATIONAL NON-PROPRIETARY NAME</td>
</tr>
<tr>
<td>ISO</td>
<td>INTERNATIONAL ORGANISATION FOR STANDARDISATION</td>
</tr>
<tr>
<td>ITF</td>
<td>INNOVATION TASK FORCE</td>
</tr>
<tr>
<td>IVMPs</td>
<td>IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCTS</td>
</tr>
<tr>
<td>MA</td>
<td>MARKETING AUTHORIZATION</td>
</tr>
<tr>
<td>MAA</td>
<td>MARKETING AUTHORIZATION APPLICATION</td>
</tr>
<tr>
<td>MAH</td>
<td>MARKETING AUTHORIZATION HOLDER</td>
</tr>
<tr>
<td>MedDRA</td>
<td>MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES</td>
</tr>
<tr>
<td>MRL</td>
<td>MAXIMUM RESIDUE LIMIT</td>
</tr>
<tr>
<td>MUMS</td>
<td>MINOR USES AND MINOR SPECIES</td>
</tr>
<tr>
<td>NCA</td>
<td>NATIONAL COMPETENT AUTHORITY</td>
</tr>
<tr>
<td>No</td>
<td>NUMBER</td>
</tr>
<tr>
<td>NRG</td>
<td>(INVENTED) NAME REVIEW GROUP</td>
</tr>
<tr>
<td>NTA</td>
<td>NOTICE TO APPLICANTS</td>
</tr>
<tr>
<td>OECD</td>
<td>ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT</td>
</tr>
<tr>
<td>OJEU</td>
<td>OFFICIAL JOURNAL OF THE EUROPEAN UNION</td>
</tr>
<tr>
<td>PAES</td>
<td>POST-AUTHORISATION EFFICACY STUDIES</td>
</tr>
<tr>
<td>PASS</td>
<td>POST-AUTHORISATION SAFETY STUDIES</td>
</tr>
<tr>
<td>PD/PK STUDIES</td>
<td>PHARMACODYNAMICS/PHARMACOKINETIC STUDIES</td>
</tr>
<tr>
<td>PDCO</td>
<td>PAEDIATRIC COMMITTEE</td>
</tr>
<tr>
<td>Ph. Eur.</td>
<td>EUROPEAN PHARMACOPOEIA</td>
</tr>
<tr>
<td>PIP</td>
<td>PAEDIATRIC INVESTIGATION PLAN</td>
</tr>
<tr>
<td>PM</td>
<td>PROCEDURE MANAGER</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>PPD</td>
<td>PROTECTED PERSONAL DATA</td>
</tr>
<tr>
<td>PRAC</td>
<td>PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE</td>
</tr>
<tr>
<td>PREA</td>
<td>PAEDIATRIC RESEARCH EQUITY ACT</td>
</tr>
<tr>
<td>PRIME</td>
<td>PRIORITY MEDICINES</td>
</tr>
<tr>
<td>PSMF</td>
<td>PHARMACOVIGILANCE SYSTEM MASTER FILE</td>
</tr>
<tr>
<td>PSUR</td>
<td>PERIODIC SAFETY UPDATE REPORT</td>
</tr>
<tr>
<td>PUMA</td>
<td>PAEDIATRIC USE MARKETING AUTHORISATION</td>
</tr>
<tr>
<td>Q&amp;A</td>
<td>QUESTIONS &amp; ANSWERS</td>
</tr>
<tr>
<td>QPPV</td>
<td>QUALIFIED PERSON FOR PHARMACOVIGILANCE</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>RESEARCH &amp; DEVELOPMENT</td>
</tr>
<tr>
<td>Rev.</td>
<td>REVISION</td>
</tr>
<tr>
<td>RMP</td>
<td>RISK MANAGEMENT PLAN</td>
</tr>
<tr>
<td>SAG</td>
<td>SCIENTIFIC ADVISORY GROUP</td>
</tr>
<tr>
<td>SAWP</td>
<td>SCIENTIFIC ADVICE WORKING PARTY</td>
</tr>
<tr>
<td>SAWP-V</td>
<td>SCIENTIFIC ADVICE WORKING PARTY - VETERINARY</td>
</tr>
<tr>
<td>SME</td>
<td>MICRO, SMALL AND MEDIUM SIZED ENTERPRISES</td>
</tr>
<tr>
<td>SmPC</td>
<td>SUMMARY OF PRODUCT CHARACTERISTICS</td>
</tr>
<tr>
<td>SOP</td>
<td>STANDARD OPERATING PROCEDURE</td>
</tr>
<tr>
<td>SUSARs</td>
<td>SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTIONS</td>
</tr>
<tr>
<td>TSE</td>
<td>TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY</td>
</tr>
<tr>
<td>US(A)</td>
<td>UNITED STATES (OF AMERICA)</td>
</tr>
<tr>
<td>VHP</td>
<td>VOLUNTARY HARMONISATION PROCEDURE</td>
</tr>
<tr>
<td>VICH</td>
<td>INTERNATIONAL COOPERATION ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF VETERINARY MEDICINAL PRODUCTS</td>
</tr>
<tr>
<td>WHO</td>
<td>WORLD HEALTH ORGANISATION</td>
</tr>
<tr>
<td>XEVMPD</td>
<td>EXTENDED EUDRAVIGILANCE MEDICINAL PRODUCT DICTIONARY</td>
</tr>
<tr>
<td>XEVPRM</td>
<td>EXTENDED EUDRAVIGILANCE PRODUCT REPORT MESSAGE</td>
</tr>
</tbody>
</table>